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  13Abstract 
 
  Asthma is one of the most common chronic diseases in the world, affecting 
approximately 300 million people worldwide.  Asthma has many phenotypes, 
allergic asthma being the most common form.  Most cases are initiated by IgE 
antibodies, generally referred to as IgE-mediated allergic asthma.  Treatments 
include β2-agonists and inhaled corticosteroids, although there is no definitive 
cure for the disease.  Asthma results in a plethora of pathological processes, 
present in many types of asthma.  This can make differential diagnosis difficult, 
although several processes are characteristic of the disease pathology including; 
airway remodelling, airways hyperreactivity and airways inflammation.   
  The interaction of mast cells and human airway smooth muscle (HASM) cells 
play an important role in the characteristic pathological processes involved with 
asthma.   
 The recently discovered cytokine, interleukin 33 (IL-33), is thought to play an 
important role in a variety of autoimmune diseases; including asthma and atopic 
dermatitis.   
  The aims of this study were to investigate the interaction of mast cells and 
HASM cells in vitro, analysing the adhesion molecules involved and the 
potential presence of chemokines relevant to the adhesion process.  In addition, 
the effects of IL-33 on the above processes were also investigated.   
  HMC-1 cells were analysed for the presence of several adhesion molecules, 
using a primary and secondary antibody, which were quantified using a 
fluorescently activated cell sorting machine (FACS).  Once the presence of the 
adhesion molecules were ascertained, the effects of IL-33 on the adhesion 
molecule expression was performed.  Anti-TNF-α therapies were also used to 
  14assess whether a change in adhesion molecule expression, on the HMC-1 cells, 
was apparent.   
    The results confirm the presence of the adhesion molecules intracellular 
adhesion molecule 1 (ICAM-1), and Integrins α4 and β1.  The presence of  
IL-33 (21 hours exposure) resulted in an up regulation of ICAM-1 on  
HMC-1 cells, being statistically different to the HMC-1 cells left untreated 
(99% confidence level).  IL-33 seemed to have little effect on Integrin α4 or β1 
expression on the HMC-1 cells.  The anti-TNF-α therapies lead to a decrease in 
ICAM-1 expression on HMC-1 cells, after being exposed to both TNF-α and 
IL-33.  This reduction in ICAM-1 expression was statistically different to the 
positive controls (HMC-1 cells treated with TNF-α alone) using both  
anti-TNF-α therapies with TNF-α and IL-33, at the 95% confidence level.   
  The effects of IL-33 on HMC-1 cell/HASM cells could lead to differences in 
adhesion, via ICAM-1.  These effects may also lead to HMC-1 cells releasing 
TNF-α, having an autocrine effect on the HMC-1 cells. 
    Recommendations for future work include; analysing other adhesion 
molecules relevant to mast cell/HASM cell interactions, including tumour 
suppressor in lung cancer-1 (TSLC-1) and vascular cell adhesion molecule-1 
(VCAM-1).  Using mast cells derived from human umbilical cord blood stem 
cells would represent an improvement to using HMC-1 cells.  In vivo research 
would also prove invaluable, quantifying and localising mast cells in asthma 













































  161.1 Overview of lung anatomy and physiology 
 
  The lungs are located in the thoracic cavity, composed of a spongy texture and 
are honeycombed with a moist epithelium that serves as the respiratory surface 
(Campbell et al., 1999).  During respiration, air passes into the trachea, which is 
made up of rings of cartilage helping it to maintain its structure.  The trachea 
then branches into two bronchi, leading to each of the lungs.  Within the lung, 
these bronchi divide further into finer tubes called bronchioles (Campbell et al., 
1999).  The epithelium lining the major branches of the trachea and subsequent 
bronchi are covered by cilia and a thin film of mucous.  The mucous traps 
contaminants (i.e. pollen and dust), which is transported by the cilia towards the 
pharynx, where it is swallowed into the oesophagus (Campbell et al., 1999). 
This process helps cleanse the respiratory system. 
 
1.2   Aetiology of asthma 
  The definition of asthma has changed repeatedly over the past several decades.  
In particular asthma is no longer regarded as a condition defined by a 
physiological, functional parameter.  It is now has cellular and biochemical 
components, increasing the complexity of the diseases pathology (Johanssen et 
al., 2004).   
  Asthma has many phenotypes, which are summarised below: 
 
1.2.1 Allergic asthma 
  The most common form of asthma is allergic asthma (Lung 2008).  Most cases 
are initiated by immunoglobulin E (IgE) antibodies, generally referred to as 
IgE-mediated allergic asthma (Johanssen et al., 2004).  The causes of allergic 
  17asthma include: pet dander, pollen and dust mites, wood dust, smoke, irritants, 
chemicals, viral/bacterial infections, stress and the emotional state of the patient 
(Lung 2008). 
  Most childhood asthma is considered an allergic type of asthma, occurring 
more often in young boys than girls.  Research has shown that maternal 
smoking can contribute to asthma or other impairment of infant lung function, 
even before the child is born.  Continued exposure to cigarette smoking can 
irritate the respiratory tract and make infants and children particularly 
vulnerable to allergic asthma (Floreani et al., 1999). 
 
1.2.2 Intrinsic asthma/Non-atopic asthma 
  Intrinsic asthma is not likely to develop in children; its typical onset occurs 
after the age of 40.  Possible causes of intrinsic asthma include respiratory 
irritants such as; perfumes, cleaning agents, fumes, smoke and cold air, upper 
respiratory infections, and gastroesophageal reflux (GERD) (Braman, 2003). 
   
1.2.3 Exercise induced asthma 
  At least eleven percent of the non-asthmatic population in the UK experience 
exercise-induced asthma (Lung, 2008).  Many of these people have allergies or 
a family history of allergies. 
   Exercise-induced asthma can affect anyone at any age and can be attributed to 
the loss of heat and moisture in the lungs that occurs with strenuous exercise.  
Frequent coughing during exercise may be the only symptom of  
exercise-induced asthma, although during cold and dry conditions,  
exercise-induced asthma symptoms can become more severe (Lung, 2008).  
  181.2.4 Nocturnal Asthma 
  Nocturnal asthma normally affects people when they are sleeping.  Asthmatic 
symptoms can occur regardless of the time of day a person is sleeping, although 
they tend to be quite severe between midnight and 4am.  Nocturnal asthma can 
be triggered by allergens in bedding or the bedroom, a decrease in room 
temperature and GERD (Lung, 2008).  Approximately 75% of asthmatic 
patients in the UK are awakened by asthmatic symptoms at least once per week, 
with approximately 40% experiencing nocturnal symptoms on a nightly basis 
(Sunderland, 2005). 
 
1.2.5 Occupational asthma 
  Occupational asthma occurs directly as a result of breathing chemical fumes, 
wood dust, or other irritants over long periods of time.  A total of 200 agents 
have been implicated in causing occupational asthma in the workplace  
(Chan-Yeung et al., 1994).   
 
1.2.6 Steroid resistant asthma 
  Overuse of asthma medications, such as steroidal based drugs, can lead to 
status asthmaticus, a severe asthma attack that doesn't responds to medication 
and may require mechanical ventilation to reverse (Lung, 2008).   
 
1.2.7 Hereditary predisposition 
  Ober et al., conducted a review investigating genetic factors that can 
predispose individuals to asthma and atopy.  Their review identified 54 genes 
across 6 populations studied, with 25 being associated with  
  192-5 population-based studies.  Genome wide-linkage analysis revealed several 
genes associated with asthma and atopy, in particular; chromosomes 5q31–33, 
6p21, and 12q13–q24 (Ober et al., 2006).  At least 14 genes in the 5q region 
have been associated with an asthmatic or atopic phenotype, several of which 
are responsible for interleukin 4 (IL-4) and IL-13 synthesis, cytokines important 
in the pathophysiolgy of the disease (Wills-Karp and Ewat, 2004).     
  ADAM33 is a member of a family of genes that encode membrane-anchored 
zinc-dependent metalloproteinases that are implicated in cell–cell interactions, 
cell fusion and cell signalling (Eerdewegh et al., 2002).  One of two known 
ADAM33 transcripts are expressed in human airway smooth muscle and airway 
fibroblasts, which may indicate that it is involved in the remodelling of airway 
tissues (Eerdewegh et al., 2002).  So far, at least 54 single nucleotide 
polymorphisms (SNPs) have been identified (Eerdewegh et al., 2002).  These 
results indicate that SNPs in ADAM33 could result in variations of protein 
levels, although further research is needed to fully elucidate ADAM33s role in 
asthma (Wills-Karp and Ewat, 2004). 
   Allergic asthma is most relevant to the work presented in this dissertation and 
therefore most of the following discussion will relate to it.   
 
1.3 Pathophysiology 
    Asthma results in a plethora of pathological processes, present in many types 
of asthma.  This can make differential diagnosis difficult, although several 
processes are characteristic of the disease pathology: 
 
 
  201.3.1 Airways Inflammation 
  Once an individual becomes sensitized to a certain allergen, subsequent 
exposure can result in an inflammatory cascade, resulting in inflammatory cells 
becoming activated (National Jewish Health, 2006).  Inhaled allergen challenge 
in allergic patients leads to an early phase allergic inflammatory reaction
 and in 
some cases this may be followed by a late-phase reaction (Bousquet et al., 
2000).  During the early phase inflammatory process, the airway lumen 
becomes filled with mucous composed of plasma proteins exuded by the airway 
cilia, and mucous glycoproteins secreted from epithelial cells lining the airways 
(Barnes, 1996).  The airway wall becomes infiltrated with inflammatory cells, 
eosinophils and lymphocytes in particular.  This leads to shedding of the airway 
epithelium resulting in clumps of epithelial cells dispersed throughout the 
airway cavity (Barnes, 1996).  Bronchoscopy of the airways reveals a swollen 
and reddened state in the asthmatic patient.  Additional diagnostic tests include 
analysis of the bronchoalveolar lavage (BAL) fluid and biopsies taken from the 
airways.  Both tests confirm the presence of macrophages, mast cells and  
T-cells all of which contribute to the inflammatory processes involved with 
asthma (Barnes, 1996).   
   
1.3.2 Airways hyper-responsiveness (AHR) 
  AHR can result in breathing difficulties and resistance to normal airflow.  
Changes in airway function are accompanied by inflammatory cell infiltrates 
composed of eosinophils, T cells, monocytes and neutrophils, as well as 
cytokines associated with a Th2 response (Brusasco et al., 1990).  This suggests 
that AHR is partially dependent on inflammatory events.   
  21  Airway remodelling may also contribute to AHR since the architecture of the 
lung is being remodelled i.e. an increased level of airways smooth muscle mass 
could lead to bronchoconstriction and partial occlusion of the trachea, which 
can contribute to an increase in breathing difficulties (Lloyd et al., 2007).   
  As the disease progresses, a decline in lung function is apparent, leading to an 
increase in breathing difficulties.   
 
1.3.3 Airway remodelling and subepithelial fibrosis 
  Airway remodelling is an ongoing process in reaction to persistent 
inflammation, as the body activates a variety of mechanisms in an attempt to 
repair the lungs.  This leads to permanent structural and functional changes. 
Airway remodelling results in different airway characteristics, for example: 
epithelial cells that line the airway are damaged and the basement membrane 
underneath becomes thicker.  An increase in the number and size of bronchial 
blood vessels is also present, suggesting that angiogenesis, the formation of 
new blood vessels from pre-existing endothelium, is an essential component of 
tissue growth and remodelling in asthma (McDonald, 2001). Additionally, the 
airways loose elasticity and the walls thicken, leading to excess muscle and 
eventually bronchoconstriction.  This can result in long-term loss of lung 
function and an increase in the severity of asthma (Lloyd et al., 2007).   
  Other theories oppose the idea that chronic inflammation is required for the 
remodelling process to occur, in particular Holgate et al., have proposed that 
reactivation of the epithelial-mesenchymal trophic unit (EMTU) contributes to 
airway remodelling.  The EMTU collectively refers to epithelial and 
mesenchymal cell mediated bidirectional growth control.  Reactivation of the 
  22EMTU can lead to excessive matrix deposition, as well as the production of 
mediators that can potentiate and intensify the remodelling responses 
throughout the airway wall (Holgate et al., 2000).  The increased matrix 
deposition seen in asthma is also likely to be caused by increased secretion 
from mesenchymal cells, myofibroblasts for example, in concert with an 
imbalance between matrix-degrading enzymes and inhibitors of these proteases 
(Lazaar and Panetierri, 2005).   
 
1.4 Prevalence 
  Asthma is one of the most common chronic diseases in the world, affecting 
approximately 300 million people worldwide (Massoli et al., 2004).  It has 
become common in both children and adults in recent decades.  Increasing 
prevalence of asthma has been associated with increases in atopic sensitization, 
along with similar increases in other allergic disorders such as eczema and 
rhinitis (Massoli et al., 2004). 
  Over 5 million people in the UK have asthma, with approximately 1.4 million 
of them being children aged less than 16 years old (British Lung Foundation, 
2008).  In the UK, it is an important cause of impaired quality
 of life, 
consumption of prescribed drugs, use of primary care,
 hospital admission and 
mortality across the whole spectrum of
 age, sex, ethnicity, socioeconomic status 





  231.5 Treatments 
  Asthma aetiology and pathophysiology can vary, coupled with the fact that 
differential diagnosis can be difficult.  Nevertheless, treatments are available 
that can ease symptoms as well as help individuals lead healthier lives.   
  Beta adrenoceptor agonists (β-agonists) were traditionally based on 
adrenaline, helping to relieve bronchoconstriction.  These non-specific 
treatments had unpleasant side effects, leading to the development of specific 
β2-adrenoceptors agonists (β2-agonists), such as salbutamol, terbutaline and 
fenoterol (Sears and Lotvall, 2004).  These fast acting treatments target the  
β2-adrenoceptors located within bronchial smooth muscle, offering short term 
relief.  Other β2-agonists, such as Formoterol and salmeterol, have longer 
durations of action and can also be combined with inhaled corticosteroids 
(Sears and Lotvall, 2004).  This combination improves lung function, and 
reduces symptoms and exacerbations of the asthmatic patient, compared to an 
increased dose of corticosteroids alone (Sears and Lotvall, 2004).   
  The long term effects of using long-acting β2-agonists can result in the 
development of tolerance to the bronchoprotective role.  Other research groups 
have reported an increase in patient morbidity and mortality from long-term 
usage of β2-agonists, especially fenoterol (Spitzer et al., 1992).   
  Inhaled corticosteroids are widely used to treat cases of moderate to severe 
cases of asthma.  Their anti-inflammatory effects help to reduce bronchial 
inflammation as well as improving pulmonary function (Boushy, 2005).   
  The combined usage of long-acting β2-agonists and inhaled corticosteroids has 
lead to an improvement in clinical effectiveness, possibly through 
complementary modes of action (Remington et al., 2005).   
  241.6 Immune responses and asthma pathogenesis 
  T cell responses to irritants, such as viral infections or allergens, are thought to 
trigger asthmatic symptoms in genetically predisposed individuals.  T-cell 
activation is initiated through the interaction of the T-cell receptor on T cells 
and major histocompatibility complex II (MHC class II) molecules on the 
surface of dendritic cells (DC).  Further interaction of CD80 and CD86 on DCs 
with their respective receptors on T cells (CTLA4 and CD28) enables T-cell 
activation to proceed (Willis-Karp and Ewat, 2004).  In asthmatic individuals, 
antigen presentation is thought to result in the polarization of T cell 
differentiation towards a Th2 pattern; whereas T cells from non-atopic,  
non-asthmatic individuals show the opposing Th1 (IFN-γ and IL-2) pattern of 
cytokine secretion (Figure 1) (Karp et al., 2000).  Activated Th2 cells secrete a 
panel of cytokines, such as IL-4 (essential for T-cell survival and expansion, as 
well as B cell differentiation), IL-13 and IL-5 (Figure 1).  IL-13 activates a 
receptor complex that is composed of the IL-4R  and IL-13R 1 on many cell 
types (figure 1) in the airway wall and is thought to mediate many processes 
that are relevant to asthma pathology (Willis-Karp and Ewat, 2004).  In 
particular, IL-5 and IL-13 secretion results in mass eosinophilic infiltration of 
the airways (Figure 1) (Saelta and Tevato, 2001).  The small airways become 
saturated with eosinophils in the "outer" section of the airway wall (between the 
smooth muscle and alveolar attachments), whereas the greatest density of 
eosinophils in the large airways is in the "inner" section of the airway wall 
(between the smooth muscle bundles and the basement membrane) (Saelta and 
Tevato, 2001). 
 
  251.6.1 Early-phase asthmatic reaction.   
1.6.1.1 Mast cells 
  The most important cell type in the early-phase asthmatic reactions (EAR) is 
the mast cell (Venkatesha et al., 2007).  Mast cell activation in asthma is driven 
by exposure of the airways to inhaled aeroallergens, as well as in response to 
cytokines released from Th  cells 2 .  This causes cross-linking of allergen-
specific IgE bound to the mast cell high affinity IgE receptor FcεRI
  
(Cruse et al., 2005).  After immunological activation via the IgE receptor, the 
mast cell releases a variety of cytokines, lipid-derived mediators, amines, 
proteases and proteoglycans.  These substances have the propensity to regulate 
adjacent cells and the metabolism of the extracellular matrix of connective 
tissues (Stevens and Austen, 1989).  The cytokines released from mast cells 
also have an important role with the late-phase asthmatic reaction (LAR), 
discussed later on.  Alternative mast cell stimuli include: proteases, adenosine 
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Figure 1.  Innate and adaptive immune responses involved with asthma.  
Words in red in the figure represent candidate genes, with evidence for linkage 
to asthma.  ADAM33 (a disintegrin and metalloproteinase 33), DPP10 
(dipeptidyl peptidase 10), PHF11 (plant homeodomain (PHD) finger  
protein-11), C5 (complement factor 5), TIM1 (T-cell immunoglobulin and 
mucin-domain containing molecules).  Adapted from Willis-Karp and Ewat 






  271.6.1.2 Basophils 
  Basophils also express the IgE receptor Fc RI and degranulate after  
re-exposure to allergen.  CC-chemokines such as; CCL11, CCL24 (eotaxin-2), 
CCL26 (eotaxin-3), CCL7, CCL13 and CCL5, IL-3, IL-5, granulocyte 
macrophage colony stimulating factor (GM-CSF) and histamine-releasing 
factor can induce basophil mediator release (Prussin and Metcalfe, 2006).  As 
well as stimulating the release of histamine and leukotrienes, CCL11 and 
CCL24 are also chemoattractant for basophils (Forssmann et al., 1997).   
  Basophils produce a spectrum of mediators, including histamine, leukotrienes, 
IL-4, and IL-13 (Schroeder et al., 2001)
 
1.6.2 Late-phase asthmatic reactions 
  The LAR involves excessive inflammation of the airways resulting in several 
structural changes, airways remodelling for example.  These changes are 
induced by various mediators derived from inflammatory cells, such as; 
eosinophils, neutrophils, mast cells, T cells, macrophages, dendritic cells (DCs), 
endothelial cells, airway smooth muscle cells (ASM) and bronchial epithelial 
cells (BECs).   
 
1.6.2.1 Eosinophils 
  In most asthma phenotypes, there are increases of eosinophils in the tissues, 
blood and bone marrow and, in general, raised numbers correlate with disease 
severity.  Eosinophils are able to produce a variety of inflammatory mediators 
that have the potential to participate in mucosal damage (Figure 2).  
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Figure 2.  Inflammatory mediators derived from eosinophils.  Abbreviations: 
ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; EPO, 
eosinophil peroxidase; FGF, fibroblast growth factor; GM-CSF, 
granulocyte/macrophage-colony stimulating factor; HB-EGF, heparin-binding 
epidermal growth factor; 15-HETE, 15-hydroxy-eicosatetraenoic acid; IFN, 
interferon; IL, interleukin; MBP, major basic protein; MCP, monocyte 
chemotactic protein; MIP, macrophage inflammatory protein; MMP, matrix 
metalloproteinase; NGF, nerve growth factor; PAF, platelet activating factor; 
PDGF, platelet-derived growth factor; PG, prostaglandin; RANTES, regulated 
on activation normal T-cell expressed and secreted; SCF, stem cell factor; TGF, 
transforming growth factor; TNF, tumour necrosis factor; VEGF, vascular 
endothelial growth factor.  Adapted from Kay, 2005 (Kay, 2005).   
 
  29They include basic granular proteins, membrane-derived lipids, chemokines, 
cytokines, fibrogenic and growth factors, in addition to reactive oxygen species 
and neuropeptides (Figure 2) (Kay, 2005).  Other fibrogenic and growth factors 
released from eosinophils are likely to be involved with the repair and 
remodelling processes associated with asthma as well.   Eosinophils involved in 
the inflammatory response also produce large amounts of free radicals, such as 
superoxide and peroxynitrite (Maddox and Shwartz, 2002).  These free radicals 
have the potential to cause further damage to neighbouring cells and tissues.     
 
1.6.2.2 Neutrophils 
   Neutrophils produce a variety substances, including leukotrienes, cytokines 
(IL-1β, IL-6, TNF-α, TGF-β, CXCL8), proteases (elastase, collagenase, matrix 
metalloproteinase (MMP) 9), microbiocidal products (lactoferrin, 
myeloperoxidase, lysozyme), reactive oxygen intermediates (superoxide, 
hydrogen peroxide, OH
−) and nitric oxide (NO) (Wenzel, 2001) 
Secretion of these products can cause airway narrowing, increased mucous 
secretion and increased ASM responsiveness (Gibbon et al., 2001).   
 
1.6.2.3 T cells 
  Cytokines secreted from Th1 and Th2 cells are heavily involved in the 
pathogenesis of asthma. Th2 cells secrete cytokines, such as IL-3, IL-4, IL-5, 
IL-6, IL-9, IL-10, IL-13 and GM-CSF, exerting a plethora of inflammatory 
effects.  During the early stages of asthma, Th2 cytokines are responsible for the 
production of IgE (Kuipers and Lambrecht, 2004).  In later stages of asthma, 
these cytokines are responsible for the ongoing inflammation. Th1 cells secrete 
  30cytokines, such as IFN-γ, IL-2, IL-12, IL-18, TNF-α, and TNF-β (Mosman and 
Sad, 1996).  
Chemokine production is also slightly different in Th1 and Th2 cells. Th1 cells 
produce CCL5, and Th2 cells produce CCL1 and CCL22 (macrophage-derived 
chemokine (MDC) (Smit and Lukacs, 2006).   
 
1.6.2.4 Dendritic cells 
  Dendritic cells (DCs) are involved in both antigen presentation and the LAR.  
Increased numbers of DCs in asthmatic airways could be responsible for the 
persistence of chronic T cell-mediated allergic inflammation.  Once allergen-
specific Th2 cells are recruited into the lung, repeated allergen presentation by 
lung DCs may drive the persistent stimulation of allergen-specific memory Th2 
cells.  Repeated Th2 cell stimulation exacerbates acute asthma episodes and 
consequently perpetuates the state of chronic inflammation that contributes to 
the airways remodelling and AHR, consistent with chronic asthma (Lipscomb 
and Masten, 2002).  Depending on the stimulus, human DCs are able to 
produce CCL2, CCL3, CCL4, CCL17, CCL22 and CXCL8  
(Penna et al., 2002).
 
1.6.2.5 Macrophages 
  Macrophages are recruited to the airways of asthmatic individuals following 
allergen challenge.  They secrete cytokines and chemokines, including IL-1, 
IFN-γ, TNF-α, IL-6, CCL2, CCL3, and CXCL8 (Gosett et al., 1999), leading to 
the recruitment and activation of other inflammatory cells.  Macrophages also 
inhibit allergic inflammation through the secretion of various inhibitory 
  31mediators, including prostaglandins and IL-10.  The secretion of these 
inhibitory mediators could potentially be impaired in asthmatic patients 
(Barnes, 2002). 
 
1.6.2.6 Airway smooth muscle cells 
  Human airway smooth muscle (HASM) cells behave differently in asthmatic 
patients.  They tend to proliferate faster due to altered patterns of matrix 
deposition and secrete greater amounts of connective tissue derived growth 
factor (stimulated by transforming growth factor beta (TGF-β))  
(Bradding, 2007).   
  HASM cells are also able to produce a variety of cytokines and chemokines 
that promote the recruitment of inflammatory cells, leading to the activation of 
other lung-resident cells contributing to airway remodelling
  
(Lloyd et al., 2007).  The airway remodelling process involves progressive 
occlusion of the trachea leading to AHR.  Increased muscle mass is also 
thought to contribute to the development of AHR
 
1.6.2.7 Modulation of the immune response in asthma 
 There are several other molecules and cell surface receptors that can modulate 
the immune response involved with asthma, these are mentioned below: 
  TIM1 (T-cell immunoglobulin and mucin-domain containing molecules) is 
thought to be involved with Th2 differentiation processes, through an as yet 
undefined pathway (Umetsu et al., 2005). Specifically, TIM-1 is expressed on 
CD4  T cells after activation,
+  and its expression is preferentially retained in Th  
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in Th  cells, leading to the synthesis of IL-4 but not IFN- 2 γ (Umetsu et al., 
2005).  There is also evidence to suggest that the newly discovered asthma gene 
C5 (complement factor 5) binds to its receptor (C5aR) on DCs, human 
monocytes and macrophages to induce the production of the Th1-promoting 
cytokine, IL-12 (Karp et al., 2000).   
  DPP10 (dipeptidyl peptidase 10) is thought to modulate the activity of many 
chemokines and cytokines that regulate the inflammatory process.  DPP10 is 
also expressed on central neurons, indicating that it might be important in the 
neuronal control of airway smooth-muscle tone (Kere and Laitinan, 2004).  
Furthermore, PHF11 (plant homeodomain (PHD) finger protein-11) is 
expressed on unactivated (Th0) cells and might be involved in T-cell activation 
and differentiation, as well as immunoglobulin synthesis  
(Kere and Laitinan, 2004). 
  Bradykinin is also an important mediator involved with the pathogenesis of 
asthma.  Its biosynthesis involves the action of kininogenase on vasoactive 
peptides formed during the inflammatory response from the α2 globulins; 
kininogens (Barnes, 1992).  Kininogenases include plasma kallikrein and tissue 
kallikrein.  There is also evidence for kinin activity in the BAL fluid from 
asthmatic patients, where bradykinin is likely to be formed from plasma that 
has exuded from the inflamed airways, by the action of plasma and tissue 
kallikreins (Barnes, 1992).   
  Bradykin has several effects on airway function in the asthmatic lung 
including; airway smooth muscle contraction, release of epithelial 
bronchodilators and increased mucous secretion (Barnes, 1992).     
  331.7 Mast cells  
1.7.1 Development and subtypes 
  Mast cells develop from CD34
+ bone marrow progenitors and maturation 
occurs throughout human tissues, circulating as committed immature precursor 
forms (Austen and Boyle, 2001).  During mast cell development, SCF plays an 
important role interacting via the mast cells c-Kit receptor  
(Williams and Galli, 2000).  This is confirmed by evidence from Kitamura  
et al., that mouse strains deficient in the c-Kit receptor (W/Wv) or the 
membrane-bound form of SCF, the Sl/SLd strain, were deficient in mast cells  
(Kitamura et al,. 1978).  Reconstituted mast cells were then reintroduced into 
W/Wv mice, later giving rise to immature mast cells when cultured in the 
presence of SCF (Kitamura et al,. 1978).  Other cytokines are also important for 
mast cell development and survival, including interleukin-3 (IL-3) and Th  
associated cytokines such as IL-4 and IL-9 (Metcalf et al., 1997).  
2
  Human mast cells contain measurable levels of tryptase, chymase, a cathepsin 
G-like protease, and carboxypeptidase.  Mast cells containing tryptase and 
chymase are denoted as MCTC, whereas the MCT subtype contains only 
tryptase.  MCT predominate in the alveolar septa of the lung and in the small 
intestinal mucosa, and the MCTC are mainly found in the skin and in the small 
intestinal submucosa (Metcalf et al., 1997). 
  In the normal human lung, 90% of the mast cells present consist of the MCT 
subtype; the remainder are MCTC
 (Severine et al., 2001).  Recent studies on 
asthmatic patients indicate that this balance shifts, resulting in an increase of the 
MCTC
 subtype (Bradding et al., 2006).  This shift in mast cell subtype may 
contribute to several of the pathological features associated with asthma.   
  34MCTC cell activation/degranulation usually results in chymase secretion.  Once 
secreted, chymase is able to cleave SCF at one of its amino acid sites, 
Phenylanine
159 (the 159 corresponds to the specific amino acid number), 
resulting in two other metabolites: SCF
1-159 and SCF
160-166.  The larger 
fragment, SCF
1-159,
 has an altered biological effect on MCTC
 cells resulting in 
increased histamine release (Severine et al., 2001).  Increases of histamine in 
the local microenvironment can lead to bronchoconstriction and smooth muscle 
cell activation.   
 
1.7.2 Location 
  Mast cells are widely distributed throughout vascularized tissues, epithelia, 
and in close proximity to blood vessels, nerves, smooth muscle cells,  
mucous-producing glands and hair follicles.  Mast cells are also present near 
surfaces exposed to the outside environment, including the skin, airways and 
gastrointestinal tract.  It is no coincidence that pathogens, allergens and other 
environmental agents are frequently encountered at these sites as well (Metcalf 
et al., 1997).   
 
1.7.3 Receptors and activation 
  Apart from mast cell activation via the FcεRI receptors, there are several other 
important stimuli that can lead to mast cell activation and subsequent 
degranulation (Figure 3).  Mast cell effector functions can also be stimulated by 
IgE binding to IgG receptors (FCγR1 and III activate, whereas FcγRII is 
inhibitory), complement receptors, histamine-releasing factors, and toll like 
receptors (TLRs) (Robinson, 2004).  These alternative receptors such as; TLR4, 
  35TLR2, CD48 and complement receptor 1 recognize microbes and their products 
through direct pattern recognition or pathogen associated molecular patterns 
(PAMPs).  Upon stimulation, these receptors can activate mast cells absent of 
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Figure 3.  Mast cell receptors with their associated ligands, and the products 
released after mast cell activation.  Adapted from Galli et al.,  
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1.7.4 Mediators and their effects 
  Mediators produced by mast cells can be divided into 3 groups; preformed 
mediators (e.g. histamine), newly synthesized lipid mediators  
(e.g. prostaglandins and leukotrienes), and cytokines and growth factors  
(e.g. tumour necrosis factor alpha (TNF-α) and vascular endothelial growth 
factor (VEGF)) (Prussin and Metcalfe, 2006).  These categories are not 
mutually exclusive since at least one cytokine, TNF-α, occurs as a preformed 
mediator and as a newly synthesized molecule (Prussin and Metcalfe, 2006).   
 
1.7.4.1 Preformed mediators 
  Preformed mediators are packaged within secretory granules in the mast cell 
and upon activation are released into the extracellular environment within 
minutes.  Granules released include histamine, proteases (tryptase, chymase, 
and carboxypeptidase) and proteoglycans (heparin and chondroitin sulphate E) 
(Galli et al., 2001).  Histamine secretion can result in smooth muscle 
contraction (leading to bronchoconstriction), nerve ending stimulation leading 
to vasodilation and bronchoconstriction along with mucous secretion  
(Figure 4.) (Galli et al., 2001).  The in vitro effects of tryptase include; cleavage 
of complement molecules C3 and C3a, activation of fibroblasts, accumulation 
of inflammatory cells, as well as enhancing histamine-induced smooth muscle 
contraction (Johnson and Knox, 1997).  Tryptase secretions can also lead to 
tissue degradation, as well as airway remodelling and the build up of tissue 
fluid (oedema) leading to tissue swelling (Figure 4).  Tryptase has also been 
  38used as a marker of mast cell degranulation, where increased concentrations of 
this protease have been found in the BAL fluid of asthmatic patients  
(Barnes, 2002).  Apart from the effects of the chymase on SCF mentioned 
above, it can also lead to increased mucous secretions from goblet cells, as well 
as tissue degradation (Figure 4) (Bousquet et al., 2000).   
 
1.7.4.2 Lipid mediators 
  Lipid mediators include prostaglandins, leukotrienes and inflammatory 
metabolites derived from the peroxidation of arachidonic acid.  Several of these 
lipid mediators, such as prostaglandin D2 (PGD2) and leukotriene C4 (LTC4), 
may be newly produced after mast cell activation.   
  Prostaglandins have several effects on the airways, including 
bronchoconstriction, plasma exudation, sensitization of nerve endings, and 
effects on inflammatory cells (Figure 4).  PGD2 is involved in the recruitment 
of inflammatory cells, stimulating the chemotaxis of Th2 cells, eosinophils, 
neutrophils and basophils in vitro and in vivo (Hirai et al., 2001).  Additionally, 
overproduction of PGD2 in mice results in enhanced pulmonary inflammation 
following allergen challenge (Fujitani et al., 2002), confirming its role as a  
pro-inflammatory lipid mediator.  Higher levels of PGD2 have also been 
detected in asthmatic patients BAL fluid, upon allergen challenge  
(Kosteins and Ulven, 2006).   
  Leukotriene B4 (LTB4) is a potent neutrophil chemoattractant that enhances 
neutrophil-endothelial interactions and stimulates neutrophil activation.  This 
leads to degranulation and the release of mediators, enzymes and superoxides.  
  39It also has weak effects on smooth muscle, but may contribute to airway 
narrowing by producing local oedema and increased mucous secretion  
(Figure 4) (Black et al., 1989).  LTB4 levels are also higher in asthmatic 
patients compared to controls (Montuschi and Barnes, 2002, Cap et al., 2004).   
 
1.7.4.3 Cytokines and growth factors 
  Cytokines released from activated mast cells will have an effect on the EAR as 
well as the LAR, potentially leading to persistent as well as chronic respiratory 
distress.   
  Mast cell derived TNF-α is a major pro-inflammatory cytokine, strongly 
involved in the pathogenesis of asthma (Bradding et al., 1994).  In addition, it 
up-regulates endothelial and epithelial adhesion molecules, increases AHR and 
also leads to bronchoconstriction (Figure 4).   Two recent studies have shown 
that TNF-α expression is increased in severe asthma, reflected by an increase in 
the BAL as well as increased protein expression on peripheral blood 
mononuclear cells (PBMCs) (Bradding et al., 2006).      
  Other cytokines produced by mast cells include IL-4; associated with Th2 cell 
differentiation and IgE synthesis, IL-3, GM-CSF, and IL-5; critical for 
eosinophil development and survival, IL-6, IL-8, and IL-16 (Bradding et al., 
2006).  Mast cells also secrete the pro-fibrogenic cytokines; TGF-β and basic 
fibroblast growth factor 2 (bFGF-2).  They also produce chemokines, such as 
CC-chemokine ligand-3 (CCL3).   These chemokines have the ability to 
stimulate histamine release from mast cells and basophils (Prussin and 
Metcalfe, 2006).  CCL2 and CCL11 (eotaxin-1) are also secreted from mast 
cells, involved in leukocyte attraction during inflammation.  Increased levels of 
  40CCL2 and CCL3 have also been found in the BAL fluid of asthmatics from 
several research groups (Cruikshank et al., 1995, Holgate et al., 1997) .  This 
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Figure 4.  Major mediators, cytokines, and growth factors produced by  
IgE- and antigen-dependent activation of mast cells.  Adapted from Williams et 






  421.8 Airway smooth muscle cells 
1.8.1 Development and differentiation 
  Airways smooth muscle cells (ASM) arise from pluripotent mesodermal cells 
that, under the appropriate chemical signals, become myoblasts.  Myoblasts 
then fuse together, again with the appropriate growth factors and cytokines 
present, to form muscle fibers that later develop into non-striated smooth 
muscle cells or mature ASM cells (McDonald, 1997).   
  ASM cell differentiation begins by the formation of a ring of mesenchymal 
cells immediately underlying the epithelium of the epithelial buds (McHugh, 
1995).  These rapidly form interlocking bundles that become wider and 
increasingly compact along the bronchial tree to the trachea (McHugh, 1995).  
Their orientation is perpendicular to the long axis of the airway.  The ASM 
exhibits rhythmic contractility (i.e. it is a phasic-type smooth muscle - rapid 
contraction and relaxation) soon after formation and along with the spontaneous 
airway narrowing, cause’ expansion of the tubule walls (Sparrow et al., 1995).  
This stretching is the mechanical stimulus to smooth muscle formation and lung 
growth (Sparrow et al., 1995).   
  Confocal microscopy studies of foetal pig lung show that cells localised at the 
base of the lung bud stain for α-actin and smooth muscle-myosin (an indication 
that ASM differentiation is taking place), where a new basement membrane is 
being assembled (Weichselbaum and Sparrow, 1999).  The basement 
membrane plays a critical role in ASM development by facilitating 
mesenchymal cell spreading and elongation (Weichselbaum and Sparrow, 
1999).   
  43  Neural tissue, i.e. precursor ganglia interconnected by nerve trunks and 
smaller bundles, forms a sheath over ASM layers in foetal mouse lung explants.  
These are guided by glial-derived neurotrophic factor (GDNF) that appears to 
be produced by ASM cells (Tollet et al., 2002).  This may indicate that nerve 
tissue development associated with ASM cells is, in part, dependent upon ASM 
production of the neuronal growth and survival inducing protein GDNF. 
 
1.8.2 Receptors and activation 
  Several chemokines are produced by ASM cells in vitro, after stimulation with 
several cytokines (IL-4, IL-13, IL-α, IL-1β, TNF-α and TGF-β) (Watson et al., 
1998, Moore et al., 2002).  Since ASM cells are stimulated with the above 
cytokines, it follows that the associated receptors are present on their cell 
surfaces, i.e. IL-4Rα and IL-13Rα1 (Figure 1).   
  ASM cells from asthmatic patients tend to behave differently to ASM cells 
from normal patients.  For example; in response to TGF- β, ASM cells of 
asthmatic patients produce more connective tissue growth factor (CTGF) as 
well as increased synthesis of collagen.  CTGF can lead to increased deposition 
of extracellular matrix, potentially contributing to the airway remodelling 
process (Borger et al., 2006).   
  Bradykinin can also increase IL-6, CXCL8 and PGE2 release  
(Pang and Knox, 1998).  IL-6 is a pleiotropic cytokine that has both  
pro-inflammatory and anti-inflammatory properties in asthma.   
  Activated ASM cells from asthmatic patients can also generate extracellular 
matrix (ECM) proteins.  The deposition of these matrix proteins have the 
  44potential to cause cell proliferation and contribute to airway remodelling 
(Lazaar and Panettieri, 2005).     
 
1.8.3 Mediators and their effects 
  After stimulation and subsequent activation, ASM cells release a plethora of 
chemokines, including; monocyte chemotactic protein-1 (MCP-1), CCL5, 
CCL7, CCL11, CCL13, and CXCL8 (Watson et al., 1998, Moore et al., 2002).  
These chemokines are involved with the recruitment of inflammatory cells into 
the lung and promote the upregulation of adhesion molecules on the cell 
surface.  Furthermore, GM-CSF (an important stimulator of maturation, 
activation and survival of several inflammatory cells), is produced by ASM 
cells when stimulated by a combination of IL-1β and TNF-α (Saunders et al., 
1997).  In particular, GM-CSF promotes stem cell differentiation into 
granulocytes and monocytes.   
  ASM cells secrete a wide variety of matrix proteins, including fibronectin, 
collagen, and laminin.  These proteins are increased in asthmatic patients 
(Lazaar and Panettieri, 2005).  Fibronectin is an important glycoprotein that 
helps stabilize the attachment of the ECM to cells lining the airway, whereas 
laminin is the major non-collagenous component of the basal lamina of 
epithelial cells.  Recent studies have demonstrated that ASM cells also secrete 
VEGF, which is an efficacious endothelial mitogen that increases fibronectin 
expression by ASM cells (Lazaar and Panettieri, 2005).  Johnson et al. have 
also shown that ECM proteins secreted by ASM cells from asthmatic patients 
differ from non-asthmatic ASM cells (Johnson et al., 2005).  Cells plated on the 
ECM derived from asthmatic ASM cells displayed greater rates of proliferation 
  45(Johnson et al., 2005).   In addition to altering ASM cell proliferation, ECM 
composition also effect ASM cell survival, for example; Fibronectin, laminin, 
and collagens I and IV have anti-apoptotic properties (Lazaar and Panettieri, 
2005).       
 
1.9 Interaction of mast cells and HASM cells 
  Although human mast cells (HMCs) and HASM cells interact with numerous 
other inflammatory cells, contributing to the pathogenesis of asthma, the 
remainder of this dissertation will
 focus on how they interact with each other 
and how these interactions contribute to the characteristic
 changes seen in 
asthma.   
 
1.9.1 HMC mediators: their effects on HASM cells 
  Roughly three quarters of the mediators released by activated HMCs
 have an 
effect
 on HASM cells.  Their effects can be divided into several
 broad 
categories related to the functions of the HASM and its
 altered characteristics in 
asthma. 
  The release of histamines, tryptase, LTD4, via matrix metalloproteinase 
(MMP-1), low concentrations of TNF- , low concentrations of PGE2 and  
TGF-  all have a proliferative effect on HASM cells.   
TNF- , at concentrations ranging from 0.3 to 30pM, can
 stimulate proliferation 
via the TNF-  p55 receptor present on HASM cells (Amrani et al., 1996).  
LTD4 on the other hand,
 indirectly induces proliferation by stimulating an 
increase in
 MMP-1, which leads to the proteolysis
 of insulin growth factor 
binding protein allowing more insulin
 growth factor to bind to its receptor and 
  46induce proliferation (Rajah et al., 1996, Reynolds et al., 1998).  While TGF- 1 
is capable of converting human lung fibroblasts into myofibroblasts 
(Broekelmann et al., 1991). 
 This conversion could possibly be an explanation
 
for the presence of fibrosis and increased bulk of muscle present
 in the airways 
of asthma patients (Broekelmann et al., 1991, Hashimoto et al., 2001).  
  The release of heparin, IL-4, high concentrations of TNF-  and high 
concentrations of PGE2 all have an anti-proliferative effect on HASM cells.  At 
a concentration of 300pM, TNF-  has indirect anti-proliferative effects by; 
reducing
 the proliferative effects of mitogens acting on G protein-coupled
 
receptors, such as thrombin, and on receptors having intrinsic
 tyrosine kinase 
activity such as epidermal growth factor (Stewart et al., 1995).  IL-4 inhibits 
HASM cell proliferation by inhibiting
 cyclin D1, an important protein for cell 
cycle progression into
 G1 as well as inhibiting proliferation induced by 
mitogens such
 as thrombin (GTP-coupled receptor) or epidermal growth factor
 
(intrinsic tyrosine kinase-coupled receptor) (Hawker et al., 1998).   
 
1.9.2 Chemotaxis and adherence of HMCs to HASM cells 
  HASM cell production of IL-6, IL-8, RANTES, GM-CSF, eotaxin, and  
MCP-1 results in the recruitment and activation of several key inflammatory 
cells in asthma.  In particular, stimulated HASM cells are capable of interacting 
with
 HMCs through the release of cytokines and surface protein
 expression 
(Ammit et al., 2000).   
  SCF exists in two forms: a membrane-bound form and a smaller soluble form 
(sSCF), which
 is thought to be the cleaved extracellular portion of the 
membrane-bound
 form (Broudy, 1997).  SCF is chemotactic and the primary 
  47regulating factor
 for HMC growth, function, and survival (Bischoff and 
Dahinden, 1992, Broudy, 1997).  Therefore, HASM cells releasing SCF will 
have the ability
 to recruit, activate, and sustain HMCs within its 
microenvironment, subsequently promoting
 inflammation.  IL-8 is also 
chemotactic for HMCs, possessing both CXCR1 and CXCR2 receptors specific 
to IL-8 (Lippert et al., 1998).  The most abundantly expressed chemokine 
receptor on HMCs is actually CXCR3.  This chemokine can induce HMC 
migration towards HASM cells since they express the CXCR3 ligand, 
CXCR10.  In particular, HASM cells from asthmatic patients show increased 
levels of CXCR10 compared to healthy controls.  This could explain the 
increased levels of HMCs in the HASM layers of asthmatic patients  
(Brightling et al., 2005).  The HASM cell expression of CXCR10 is also 
inducible by TNF-α, released by HMCs, and IL-4, one of the characteristic 
cytokines released during a Th2 response (Brightling et al., 2005).        
  PGE2, IL-6, and
 GM-CSF are thought to be involved with negative feedback 
mechanisms to suppress activated HMCs in the HASM layer. Although PGE2 
and IL-6 induce
 in vitro differentiation of cord blood mononuclear cells into
 
fully functional mature HMCs (Saito et al., 1995).   
  Once HMCs migrate towards the smooth muscle layers, they begin to attach to 
HASM cells through a variety of adhesion molecules.  In particular; 
Intercellular adhesion molecule-1 (ICAM-1), Vascular cell adhesion molecule-1 
(VCAM-1) and Integrin α4β1 (Tsang et al., 2005, Yang et al., 2006).  These 
adhesion molecules enable avid binding between HASM cells and HMCs in 
vitro, present on both cell types.  The ligands associated with the above 
adhesion molecules (ICAM-1, VCAM-1 and Integrin α4β1) include; 
  48Lymphocyte function associated antigen-1 (LFA-1), Very late activating 
antigen-4 (VLA-4) and CD14, in that order.  The adhesion molecule ligands are 
not mutually exclusive with respect to the adhesion molecule they can bind to, 
for example, Integrin α4β1 can also bind to VLA-4.    
  The tumour suppressor in lung cancer-1 (TSLC-1), present on HMCs, is also 
involved with HMC/HASM cell adhesion and binds, in part, through an as yet 
undefined Ca
2+ dependent pathway (Yang et al., 2006). 
   Binding of HMC to HASM cells results in sustained activation of both cell 
types.  This interaction could potentially lead to a prolonged inflammatory 
response as well as contribute to further airway remodelling and AHR.  The 
adhesion molecules involved in this process are of particular interest, since their 
cell surface expression is likely to be inducible by external substances released 
in the local microenvironment.  Tsang et al., have reported the synergistic 
effects of TNF-α and SCF on the cell surface expression of ICAM-1 on human 
mastocytosis cell line-1 (HMC-1) cells (structurally and functionally similar to 
HMCs), after 48 hours of exposure (Tsang et al., 2005).  TNF-α alone is also 
able to up-regulate ICAM-1 expression on HMC-1 cells (Tsang et al., 2005).  
HMCs are therefore producing TNF-α which could have an autocrine effect, 
possibly leading to a modulation of cell surface adhesion molecule expression.  
In addition, the synergistic effects of both TNF-α and SCF in  
up-regulating ICAM-1 expression on HMC-1 cells is a concomitant product of 
the cytokines released from both HMC and HASM cells.  The ability to 
modulate cell surface adhesion molecules present on HMC-1 cells makes it an 
attractive target for investigation, especially in light of HMC/HASM cell 
interactions and subsequent contribution to the pathogenesis of asthma.                    
  491.10 Interleukin-33 
  HMC/HASM cell interactions can be influenced by a variety of cytokines, 
released from other immune molecules involved in asthma.  One such cytokine, 
Interleukin-33 (IL-33), is thought to play an active role in a variety of 
inflammatory disorders including asthma (Schmitz et al., 2005, Allakhverdi et 
al., 2007).  In particular, there is a growing body of evidence that implicates  
IL-33 and it’s ability to activate as well as promote the survival of HMCs both 
in vitro and in vivo (Iikura et al., 2007, Ali et al., 2007, Ho et al., 2007).  In 
addition, IL-33 mRNA has been shown to be expressed on a variety of immune 
cells, including HASM cells (Schmitz et al., 2005).  These findings make the 
study of IL-33 and it’s involvement with HMC/HASM cell interactions an 
interesting avenue for further investigation.          
 
1.10.1 Structure and location 
  IL-33 is a recently identified member of the IL-1 family of molecules (IL-1 
and IL-18 for example) (Iikura et al., 2007).  IL-33 consists of 270 amino acids 
with an atomic mass of 30.7kDa.  It is synthesized as a 31-kDa protein that 
lacks a clear signal peptide (Schmitz et al., 2005).  This IL-33 precursor has 
been shown to be cleaved by caspase-1 into its mature form, in vitro, although 
there is a lack of in vivo evidence to support this statement  
(Carriere et al., 2006).     
  HASM cells, as well as epithelial cells, forming the bronchus or small airways 
demonstrate a constitutive expression of IL-33 mRNA.  Primary lung or dermal 
fibroblasts and keratinocytes stimulated with TNF-α and IL-1β also induce  
  50IL-33 gene expression (Schmitz et al., 2005).  In addition, activated dendritic 
cells and macrophages express low levels of human IL-33 mRNA  
(Schmitz et al., 2005).   
 
1.10.2 Co-receptors and location 
  IL-33 is the natural ligand
 of ST2, an orphan member of the IL-1 receptor 
superfamily (Allakhverdi et al., 2007).  The gene encoding the IL-33 receptor 
also encodes a soluble
 molecule (sST2) by alternative splicing as well as a 
variant
 form expressed in humans, ST2v, the functions
 of which are unclear  
(Xu et al., 1998).   
  The ST2 receptor consists of an IL-33Rα-chain and a β-chain.  These 
transmembrane proteins form a heterodimer, resulting in the close association 
of the cytosolic Toll-like IL-1R (TIR) homology domains (Martin and Wesche, 
2002).  The recently identified β-chain of ST2, the IL-1 receptor accessory 
protein (IL-1RAcP), has been proposed to be essential for IL-33 signalling, and 
the TIR domains of both chains are required to facilitate this signalling (Ali et 
al., 2007).  IL-1RAcP represents the β-chain necessary for IL-33 to induce 
responses in Th2 cells and murine bone marrow-derived mast cells (Ali et al., 
2007).    
  The ST2 receptor is preferentially expressed on Th2 but not Th1 cells, mature 
mouse mast cells (MCs) and also on cultured bone marrow-derived
 immature 
mast cells (Mortiz et al., 1998).   
   
 
 
  511.10.3 IL-33 functions 
  IL-33 mediates its biological effects via the IL-1 receptor ST2, activates  
NF-κB and MAP kinases, and drives production of Th2-associated cytokines 
from in vitro polarized Th2 cells. In vivo, IL-33 induces the expression of IL-4, 
IL-5, and IL-13 and leads to severe pathological changes in mucosal organs  
(Xu et al., 1998).  In mice, IL-33 also induces eosinophilia, splenomegaly, and 
increased levels of serum IgE (Schmitz et al., 2005).   
  In addition, macrophage-associated ST2L as well as sST2 have been reported
 
to display anti-inflammatory properties (Brint et al., 2004).   
  Apart from its effects as a pro-inflammatory cytokine, Carriere et al., report 
that IL-33 is an endothelium-derived, chromatin-associated nuclear factor with 
transcriptional repressor properties (Carriere et al., 2007).   
  IL-33 also acts both
 alone and in concert with thymic stromal lymphopoietin 
to expedite the in vitro maturation of CD34
+ mast cell precursors, as well as 
inducing the
 secretion of Th2 cytokines and Th2-attracting chemokines 
(Allakhverdi et al., 2007).  IL-33 has also been shown to promote the survival 
and adhesion of human umbilical cord blood-derived mast cells (HUCBMCs) 
to fibronectin (released from HASM cells), as well as inducing secretions of  
IL-8 and IL-13 from HUCBMCs (Iikura et al., 2007).  IL-33 may therefore play 
an important
 role in mast cell-mediated inflammation, as well as modulation of 





  521.11 Aims of the project 
  The aims of the project are to: 
1.  Investigate the interaction of mast cells and HASM cells in vitro, firstly 
using a human mast cell line.  This will involve analysing the adhesion 
molecules involved and the potential presence of chemokines relevant to 
the adhesion process.   














































  542. Materials and Methods 
 
 
  Several experimental protocols were used during this study including; Cell 
culture of HMC-1 cells and flow cytometry.  All relevant COSHH forms can be 
located in the GBRC Level 4 laboratory COSHH handbook.   
 
2.1 Reagents 
  All cell culture media used during the project were obtained from Sigma 
Aldrich UK.  Anti-β1 integrin, α4 integrin and ICAM-1 functional blocking 
antibodies (all mouse IgG1 subtypes) were obtained from R&D systems, 
Abingdon, UK.  Isotype immunoglobulins were obtained from R&D systems 
and the phycoerytherin (PE) anti mouse IgG1 secondary antibody was obtained 
from Abcam, Cambridge, UK.  The cytokine TNF-α was donated as a kind gift 
from Lucy Balantyne, University of Glasgow, while the anti-TNF-α therapies; 
Enterecept and Adalimunab were a kind gift from Dr Axel Hueber, University 
of Glasgow.   
 
2.2 Cell Culture 
  HMC-1 cells were a kind gift of Prof Butterfield, Mayo Clinic.  HMC-1 cells 
were maintained in Iscove’s modified Dulbecco modified eagle medium 
(IDMEM) supplemented with heat inactivated bovine serum 10% and alpha 
thioglycerol.   
HMC-1 cells were kept in an incubator with 5% CO2 at 37
oC, when not being 
used during an experiment. 
  552.3 Analysis of ICAM-1 expression on HMC-1 cells using Fluorescent-
activated cell sorting (FACS) 
  In order to accurately measure ICAM-1 expression on HMC-1 cells using 
FACS, an ICAM-1 adhesion cell blocker was used.  As well as an isotype 
control, a secondary antibody was also needed to specifically bind to the 
ICAM-1.   
 
The following antibodies were used: 
 
Anti human ICAM-1 (10µg/ml) 
PE anti mouse IgG1 (secondary antibody)  
Isotype control (10µg/ml) 
 
A total of 6 tubes were used: 
Tube number and contents (all tubes contained 100 000 HMC-1 cells without 
IDMEM medium) 
 
1:  Unstained (i.e. just HMC-1 cells) 
2.  Isotype control – mouse IgG1 
3.  PE anti mouse IgG1 
4.  Isotype control – mouse IgG1 and PE anti mouse IgG1 
5.  Anti human ICAM-1 
6.  Anti human ICAM-1 and PE anti mouse IgG1 
 
  56  10µl of each reagent was added to 90µl of staining buffer (consisting of 
Phosphate buffered saline (PBS), Foetal calf serum (FCS) 0.5% and NaN3 
0.01%) and pipetted into each tube (at the concentrations listed above, not 
including the secondary antibody).   
  The tubes were then left for 30 minutes to enable binding to take place, and 
then centrifuged (1400 revolutions per minute (rpm) for 5 minutes) and 
resuspended in FACS flow (except for tubes 3 and 6).  After that, tubes 1/2/4 
and 5 were left for 30 minutes (on ice).   
  The secondary antibody was then added at a second stage (2µl in 100µl of 
staining buffer) to tubes 3 and 6, and subsequently left for 30 minutes.  After 
this, they were centrifuged a second time (1400rpm for 5 minutes) and 
resuspended in FACS flow eventually being put on ice with the other tubes.  All 
tubes were then put through the FACS machine for analysis.  Cells were 
analysed on a FACS Calibur machine (BD Bioscience, Oxford, UK). 10,000 
events were collected in the gated region and further analysis was performed 
using Flojo software (Treestar Inc, Ashland Oregeon). 
 
2.4 Analysis of ICAM-1 expression on HMC-1 cells pre-treated with IL-33, 
using FACS 
  This experiment consisted of duplicate results for each time point, except for 
the positive and negative control groups.   
  Tubes contained 200 000 HMC-1 cells with IDMEM and IL-33 was also 
added at different time points (concentration of 100ng/ml, 5µl per tube).  A 
total of six time points were used with 3 groups of negative and positive 
  57controls.  TNF-α was used as the positive control since previous experiments 
carried out by Tsang et al., demonstrated an up-regulation of ICAM-1 
expression when HMC-1 cells were exposed to TNF- α at a concentration of 
20ng/ml (Tsang et al., 2005).  The following time points were used, with IL-33 
added at these times so the tubes could be run through the FACS machine at the 
same end point: 1, 18, 20, 24, 26 and 48 hours.  A total of 48-hours exposure 
was used; since previous experiments conducted analysing ICAM-1 expression 
(using TNF-α) on HMC-1 cells used the same time frame (Tsang et al., 2005).   
  During the IL-33 time course, HMC-1 cells were kept in 24 well  
NUNC-MAXISORB Immuno plates (Fisher Scientific, UK).  After the final  
IL-33 sample was added and left for the appropriate length of time, the contents 
from the Immuno plates were transferred to Falcon tubes and subsequently 
treated/labelled as follows: 
  Tubes 1-12 were used for the different time points and tubes 13-15 were the 
positive controls (TNF-α added on day one until the end of the experiment) and 
tubes 16-18 were the negative controls.  Tubes 19-21 were used to assess the 
expression of ICAM-1 on HMC-1 cells that have had no prior treatments.  An 
extra tube was initially used to identify the location of the HMC-1 population 
during flow cytometry analysis.  This tube contained HMC-1 cells only that 
have had no prior treatments.  This tube yielded no usable result; therefore I 
have not assigned it a tube number.    
  After the final IL-33 sample was added and left for the appropriate length of 
time, tubes were centrifuged (1400 rpm for 5 minutes) and resuspended in an 
  58Fcε receptor blocker (50µl) to prevent non-specific binding by the primary and 
secondary antibodies. The tubes were then left for 15 minutes.   
The following antibodies/reagents were used to assess ICAM-1 expression on 
HMC-1 cells: 
 
Anti human ICAM-1 (10µg/ml) 
PE anti mouse IgG1 (secondary antibody)  
Isotype control (10µg/ml) 
TNF-α (20ng/ml) 
 
  10µl of each reagent was added to 90µl of staining buffer (consisting of PBS, 
FCS 0.5% and NaN3 0.01%) at the concentrations listed above, not including 
the secondary antibody.   
After the tubes were exposed to the receptor blocker, the following were added 
(100µl) to each tube along with more of the Fc epsilon receptor blocker (50µl) 
and left for 30 minutes: 
 
Tube number and content: 
 
Tubes 1-12: (IL-33 time course, at this point the IL-33 had been removed):  
Anti human ICAM-1 (10µg/ml) 
Tubes 13-15: (positive control): Anti human ICAM-1 (10µg/ml) 
Tubes 16-18 (negative control): Isotype control (10µg/ml) 
Tubes 19-21 (control): Anti human ICAM-1 (10µg/ml) no IL-33 
  59  All tubes were then centrifuged (1400rpm for 5 minutes) and respuspended 
with the secondary antibody (2µl in 100µl of staining buffer), being 
subsequently left for 30 minutes.  After this, they were centrifuged again 
(1400rpm for 5 minutes) and resuspended in FACS flow.   
  All tubes were then put through the FACS machine for analysis.  10,000 
events were collected in the gated region and further analysis was performed 
using Flojo software (Treestar Inc, Ashland Oregeon).   
 
2.5 Analysis of ICAM-1 expression on HMC-1 cells pre-treated with IL-33 
and anti-TNF-α therapies (Etanercept and Adalimumab), using FACS 
  The same protocol from 2.4 was used to assess whether using anti-TNF-α 
therapies would alter ICAM-1 expression on HMC-1 cells.  All tubes were left 
for 20 hours (except the isotype control) and subsequently processed in the 
same fashion as in protocol 2.4.  The flowing reagents were used and assigned 
to the following tubes, subsequently being treated and analysed using flow 
cytometry as in protocol 2.4: 
  The concentrations of IL-33, TNF-α and the isotype control used during this 
experiment were the same as in protocol 2.4.  The anti-TNF-α therapies used 
were Etanercept and Adalimumab.  Initially, concentrations of 100µg/ml for 
both therapies were used to ensure any TNF-α present was either inactivated 
(Adalimumab) or prevented from binding to its cell surface receptors on the 
HMC-1 cells (Etanercept).  Lower concentrations of 100ng/ml were 
subsequently used, since the higher concentration yielded low numbers of 
HMC-1 cells in the gated region, potentially being toxic to the HMC-1 cells.   
 
  60The combinations of reagents used during this protocol were: 
 
Tube number  1:  Unstained HMC-1 cells (no treatment) 
2:  Isotype control 
3: TNF-α (positive control) 
4:  No IL-33 
5:  IL-33  
                    6, 7:  IL-33 and isotype control (IgG1)  
          8, 9:  TNF-α and isotype control (IgG1) 
    10, 11:  TNF-α and Etanercept 
    12, 13:  TNF-α and Adalimumab 
    14, 15:  IL-33 and Etanercept 
    16, 17:  IL-33 and Adalimumab 
    18, 19:  Etanercept 
    20, 21:  Adalimumab 
 
2.6 Analysis of Integrins α4 and β1 expression on HMC-1 cells treated with 
IL-33, using FACS 
  The same protocol from 2.4 was used to assess whether using IL-33 would 
alter integrins α4 and β1 expression on HMC-1 cells.  The flowing reagents 
were used and assigned to the following tubes, subsequently being treated and 
analysed using flow cytometry as in protocol 2.4 (FACS Calibur machine (BD 
Bioscience, Oxford, UK): 
  61  The concentrations of IL-33, TNF-α and the isotype control used during this 
experiment were the same as in protocol 2.4.  The following time points were 
used, with IL-33 added at these times so the tubes could be run through the 
FACS machine at the same end point: 1, 18, 21, 24 and 48 hours.  The 
combinations of reagents used during this protocol were: 
 
Tube 1: unstained HMC-1 cells 
 
Tubes 2: (negative control) Isotype control (10µg/ml) 
 




Tubes 4: (control) Anti human integrin α4 and β1 (10µg/ml) no IL-33 
 
Tubes 5-24:  Time course - Anti human integrin α4 and β1 (10µg/ml)  
 
and IL-33 (100ng/ml) 
 
    10,000 events were collected in the gated region and further analysis was 




























































  633. Results 
 
  The results from the FACS machine were obtained in a similar pattern each 
time.  Firstly a preliminary experiment was set up to assess whether an 
adhesion molecules expression could be measured accurately, using 
unconjugated antibodies with a secondary antibody added at a later stage.  The 
results for ICAM-1 expression indicated a shift away from the isotype control, 
indicating that HMC-1 cells express the ICAM-1 adhesion molecule at basal 
levels.  These results have been omitted from this section.  The Mean 
Fluorescence Intensity (MFI) values were used throughout the results section, 
since the investigation was aimed at elucidating the effects of IL-33 on the 
expression of the adhesion molecules per HMC-1 cell.  Therefore the MFI is an 
average of adhesion molecule expression per HMC-1 cell, which was then 
calculated as an average from all gated HMC-1 cells expressing the adhesion 
molecule of interest begin studied at the time.   
  The raw data collected is included in an appendix (Appendix 6.1).   
 
3.1 ICAM-1 expression on HMC-1 cells exposed to IL-33 (time course)  
  MFI values obtained from the FloJo software package, used to analyse the 
FACS data, were recalculated as a percentage of the positive control (TNF-α) 
value.  This was performed in duplicate for each separate time course carried 
out on different days, enabling direct comparison of all data points collected.  
Additionally, this will enable parametric statistical analysis of the data sets 
presented here, in the results section.   
  The MFI percentages of ICAM-1 expression compared to TNF-α over the time 
course; 0, 1, 18, 20, 24, 26, 48 hours exposure to IL-33 were; 59.21%, 45.64%, 
  6465.74%, 95.32%, 76.69%, 71.18% and 67.52% respectively (Figure 5).  The 
general trend from the graph shows a slight decrease of ICAM-1 expression on 
the HMC-1 cells from 0 to 1 hour, with a sharp increase up to 20 hours of 
exposure to IL-33.  This expression then sharply decreases from 20 to 26 hours, 
with little variation in ICAM-1 expression from 26 to 48 hours exposure to  





















































Figure 5.  Time course of ICAM-1 expression on HMC-1 cells, after treatment  
 





















  663.2 ICAM-1 expression on HMC-1 cells exposed to IL-33 and TNF-α 
 
  HMC-1 cells exposed to IL-33 for 20 hours were shown to promote the 
greatest increase in up-regulating ICAM-1 expression over the time course 
carried out (Figure 5).  This up-regulation is represented graphically in the form 
of FACS plots, where a definitive shift away from the isotype control is evident  
(Figure 6).  The positive control (TNF-α) revealed the greatest increase in  
up-regulating ICAM-1 expression on HMC-1 cells of all the treatment groups, 
which is supported by the journal literature (Tsang et al., 2005).  Again this  
up-regulation is represented graphically in the form of a FACS plot, with a 
clear shift away from the isotype control (Figure 7).         
  ICAM-1 expression on HMC-1 cells exposed to IL-33 (100ng/ml) for 20 
hours and receiving no treatment compared to TNF-α treated HMC-1 cells 
were; 88.46%, 53.82% and 100% respectively (Figure 8).  The IL-33 (HMC-1 
cells treated for 20 hours), untreated and TNF-α results represent mean values 
taken from 7 repeated experiments.  The error bars for ICAM-1 expression on 
HMC-1 cells in Figure 8 do not overlap, although it cannot be assumed that the 
results are significantly different.  Consequently, further statistical analyses are 
required for clarification.   
  Using the students’ unpaired t-test to compare ICAM-1 expression of HMC-1 
cells treated with IL-33 for 20 hours and TNF-α with the untreated group, 
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Figure 6.  FACS plot of HMC-1 cells expressing ICAM-1  
 


























Figure 7.  FACS plot of HMC-1 cells expressing ICAM-1  
 
after exposure to TNF-α versus the isotype control.   
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Figure 8.  Histogram of ICAM-1 expression on HMC-1 cells, after being 
treated with IL-33 (100ng/ml) for 20 hours, TNF-α (20ng/ml) and being left 
untreated.  The ICAM-1 expression of HMC-1 cells treated with IL-33 for 20 
hours and TNF-α are both statistically different to the untreated group 
(* P< 0.01 using the students unpaired t-test).   
 






  693.3 ICAM-1 expression on HMC-1 cells exposed to anti-TNF-α therapies  
  ICAM-1 expression on HMC-1 cells exposed for 20 hours to Adalimumab 
(100ng/ml) with TNF-α, Etanercept (100ng/ml) with TNF-α and receiving no 
treatment compared to TNF-α treated HMC-1 cells were; 58.91%, 62.62%, 
53.82% and 100% respectively (Figure 9).  The anti-TNF-α therapy results at 
the concentrations stated (HMC-1 cells treated for 20 hours) represent mean 
values taken from 4 repeated experiments.  The error bars for ICAM-1 
expression on HMC-1 cells treated with the anti-TNF-α therapies, TNF-α and 
untreated HMC-1 cells do not overlap (Figure 9), although it cannot be assumed 
that the results between the HMC-1 cells treated with anti-TNF-α therapies, are 
significantly different to the HMC-1 cells treated with TNF-α and being left 
untreated.  Consequently, further statistical analyses are required for 
clarification.  Using a one way ANOVA statistical test to compare ICAM-1 
expression of HMC-1 cells treated with Adalimumab and Etanercept for 20 
hours (with TNF-α) and the untreated group with HMC-1 cells treated with 
TNF-α, revealed statistical significance in all 3 cases (P<0.05) (Figure 9).  Post 
hoc analysis of the results (Tukey test with a Bonferroni adjustment) 
specifically identified the HMC-1 cells treated with Adalimumab and 
Etanercept for 20 hours (with TNF-α) and the untreated group as being 
statistically different to the HMC-1 cells treated with TNF-α, at the 99% 
confidence level.   
  Results from the HMC-1 cells treated with anti-TNF-α therapies at higher 
concentrations (100µg/ml) revealed a dramatic reduction in ICAM-1 
expression, along with a reduction in gated HMC-1 cells in general.  This 
suggests the higher concentrations originally used were too high and may have 
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Figure 9.  Histogram of ICAM-1 expression on HMC-1 cells, after being 
treated for 20 hours with; TNF-α (20ng/ml), Adalimumab (ADA – 100ng/ml) 
with TNF-α and Etanercept (ENT – 100ng/ml) with TNF-α.  The ICAM-1 
expression of HMC-1 cells treated with TNF-α is statistically different to the 
untreated, Adalimumab with TNF-α and Etanercept with TNF-α groups  
(* P< 0.01 using an ANOVA and Tukey test statistical analysis). 
  723.4 ICAM-1 expression on HMC-1 cells exposed to anti-TNF-α therapies 
and IL-33 
  HMC-1 cells exposed to IL-33 for 20 hours were shown to promote the 
greatest increase in up-regulating ICAM-1 expression versus the other 
treatment groups.  This up-regulation is represented graphically in the form of 
FACS plots, where a definitive shift away from the isotype control is evident 
(Figures 10 and 11).  HMC-1 cells treated with Adalimumab with IL-33 and 
Etanercept with IL-33 lead to a reduction in ICAM-1 expression, comparable 
with untreated HMC-1 cell ICAM-1 expression (Figures 10 and 11).  This clear 
shift of ICAM-1 expression, away from the HMC-1 cells treated with IL-33 for 
20 hours, is evident in both cases although the Adalimumab seemed to have 
more of an effect in reducing ICAM-1 expression (Figure10) compared to 
Etanercept (Figure 11).   
  ICAM-1 expression on HMC-1 cells exposed for 20 hours to Adalimumab 
(100ng/ml) with IL-33, Etanercept (100ng/ml) with IL-33 and receiving no 
treatment compared to IL-33 treated HMC-1 cells were; 57.47%, 60.76%, 
53.82% and 88.46% respectively (Figure 12).  The anti-TNF-α therapy results 
at the concentrations stated (HMC-1 cells treated for 20 hours) represents mean 
values taken from 4 repeated experiments.  The error bars for ICAM-1 
expression on HMC-1 cells treated with the anti-TNF-α therapies, TNF-α and 
untreated HMC-1 cells do not overlap (Figure 12), although it cannot be 
assumed that the results between the HMC-1 cells treated with anti-TNF-α 
therapies are significantly different to the HMC-1 cells treated with TNF-α and 
being left untreated. 
Consequently, further statistical analyses are required for clarification. 
  73  Using a one way ANOVA statistical test to compare ICAM-1 expression of 
HMC-1 cells treated with Adalimumab and Etanercept for 20 hours (with IL-
33) and the untreated group with HMC-1 cells treated with IL-33, revealed 
statistical significance in all 3 cases (P<0.05) (Figure 12).  Post hoc analysis of 
the results (Tukey test with a Bonferroni adjustment) specifically identified the 
HMC-1 cells treated with Adalimumab and Etanercept for 20 hours (with IL-
33) and the untreated group as being statistically different to the HMC-1 cells 






















IL-33 20 hours 
 











Figure 10.  FACS plot of HMC-1 cells expressing ICAM-1  
after; 20 hours exposure to IL-33, treatment with IL-33 and  















IL-33 20 hours 
 
IL-33 20 hours 
and Etanercept
Figure 11.  FACS plot of HMC-1 cells expressing ICAM-1  
after; 20 hour exposure to IL-33, treatment with IL-33 and  






































Figure 12.  Histogram of ICAM-1 expression on HMC-1 cells, after being 
treated for 20 hours with; IL-33 (100ng/ml), Adalimumab (ADA – 100ng/ml) 
with IL-33 and Etanercept (ENT – 100ng/ml) with IL-33.  The ICAM-1 
expression of HMC-1 cells left untreated, treated with Adalimumab with IL-33 
and Etanercept with IL-33 were all statistically different to the HMC-1 cells 
treated for 20 hours with IL-33 (100ng/ml) (* P< 0.05 using an ANOVA and 




  763.5 Integrin-α4 expression on HMC-1 cells exposed to IL-33 (time course) 
  MFI values obtained from the FloJo software package, used to analyse the 
FACS data, were recalculated as a percentage of the positive control (TNF-α) 
value.  This was performed four times for each separate time course carried out 
on different days, enabling direct comparison of all data points collected.   
  The MFI percentages of integrin-α4 expression compared to TNF-α over the 
time course; 0, 1, 18, 21, 24, and 48 hours exposure to IL-33 were; 28.57%, 
45.93%, 57.49%, 42.70%, 66.91% and 44.77% respectively (Figure 13).  The 
general trend from the graph shows an increase of integrin-α4 expression on the 
HMC-1 cells from 0 to 1 hour, with a gradual increase up to 18 hours of 
exposure to IL-33.  This expression then decreases from 18 to 21 hours, 
increases from 21 to 24 hours exposure then gradually decreases from 24 to 48 
hours exposure to IL-33 (Figure 13).   
 
3.6 Integrin-α4 expression on HMC-1 cells exposed to IL-33 and TNF-α 
  HMC-1 cells exposed to IL-33 for 24 hours were shown to promote the 
greatest increase in up-regulating integrin-α4 expression over the time course 
carried out (Figure 13).  This up-regulation is represented graphically in the 
form of FACS plots, where a slight shift away from the isotype control is 
evident (Figure 14).  Integrin-α4 expression on untreated HMC-1 cells reveals 
only a slight shift away from the isotype control, with TNF-α making somewhat 
of a modest shift away from the isotype control as well.   
  Integrin-α4 expression on HMC-1 cells exposed to IL-33 (100ng/ml) for 24 
hours and receiving no treatment compared to TNF-α treated HMC-1 cells 
were; 66.91%, 44.77% and 100% respectively (Figure 15).  The IL-33 (HMC-1 
  77cells treated for 24 hours), untreated and TNF-α results represent mean values 
taken from 4 repeated experiments.  The error bars for integrin-α4 expression 
on HMC-1 cells in Figure 15 do not overlap, although it cannot be assumed that 
the results are significantly different.  Consequently, further statistical analyses 
are required for clarification.   
  Using the students’ unpaired t-test to compare integrin-α4 expression of 
HMC-1 cells treated with IL-33 for 24 hours with the untreated group revealed 
no statistical difference (P>0.05).  Conversely, integrin-α4 expression of  
HMC-1 cells treated with TNF-α compared to the untreated group were 














































Figure 13.  Time course of integrin-α4 expression on HMC-1 cells, after 
 



















































Figure 14.  FACS plot of HMC-1 cells expressing integrin-α4  
after; 21 hour exposure to IL-33, treatment with TNF-α, 












































 Figure 15.  Histogram of integrin-α4 expression on HMC-1 cells, after being 
treated with IL-33 (100ng/ml) for 24 hours, TNF-α (20ng/ml) and being left 
untreated.  The expression of integrin-α4 on HMC-1 cells treated with IL-33 for 
24 hours revealed no statistical difference to the untreated group at the 95% 
confidence level.  Integrin-α4 expression on HMC-1 cells treated with TNF-α 












  813.7 Integrin-β1 expression on HMC-1 cells exposed to IL-33 (time course) 
  MFI values obtained from the FloJo software package, used to analyse the 
FACS data, were recalculated as a percentage of the positive control (TNF-α) 
value.  This was performed four times for each separate time course carried out 
on different days, enabling direct comparison of all data points collected.   
  The MFI percentages of integrin-β1 expression compared to TNF-α over the 
time course; 0, 1, 18, 21, 24, and 48 hours exposure to IL-33 were; 72.80%, 
103.63%, 110.79%, 116.55%, 98.17% and 114.62% respectively (Figure 16).  
The general trend from the graph shows an increase of integrin-β1 expression 
on the HMC-1 cells from 0 to 1 hour, with a gradual increase up to 21 hours of 
exposure to IL-33.  This expression then decreases from 21 to 24 hours then 
gradually increases from 24 to 48 hours exposure to IL-33 (Figure 16). 
 
3.8 Integrin-β1 expression on HMC-1 cells exposed to IL-33 and TNF-α 
  HMC-1 cells exposed to IL-33 for 21 hours were shown to promote the 
greatest increase in up-regulating integrin-β1 expression over the time course 
carried out (Figure 16).  This up-regulation is represented graphically in the 
form of FACS plots, where a shift away from the isotype control is evident 
(Figure 17).  Integrin-β1 expression on untreated and TNF-α treated HMC-1 
cells also reveal a shift away from the isotype control.  HMC-1 cells treated 
with IL-33 for 21 hours produced a greater increase in the expression of 
integrin-β1 compared to TNF-α treated HMC-1 cells (Figure 17).     
  Integrin-β1 expression on HMC-1 cells exposed to IL-33 (100ng/ml) for 21 
hours and receiving no treatment compared to TNF-α treated HMC-1 cells 
were; 116.55%, 72.80% and 100% respectively (Figure 18).  The IL-33  
  82(HMC-1 cells treated for 21 hours), untreated and TNF-α results represent mean 
values taken from 4 repeated experiments.  The error bars for integrin-β1 
expression on HMC-1 cells in Figure 18 do not overlap, although it cannot be 
assumed that the results are significantly different.  Consequently, further 
statistical analyses are required for clarification. 
  Using the students’ unpaired t-test to compare integrin-β1 expression of 
HMC-1 cells treated with IL-33 for 21 hours and TNF-α with the untreated 















































Figure 16.  Time course of integrin-β1 expression on HMC-1 cells, after  
 





























Figure 17.  FACS plot of HMC-1 cells expressing integrin-β1  
after; 21 hour exposure to IL-33, treatment with TNF-α, 










































Figure 18.  Histogram of integrin-β1 expression on HMC-1 cells, after being 
treated with IL-33 (100ng/ml) for 21 hours, TNF-α (20ng/ml) and being left 
untreated.  The expression of integrin-β1 on HMC-1 cells treated with IL-33 for 
21 hours and TNF-α revealed no statistical difference to the untreated group at 




































































  874. Discussion 
 
  The results presented in this dissertation represent data involving the 
expression of various adhesion molecules on HMC-1 cells.  It is thought that 
variations in adhesion molecule expression on HMC-1 cells could lead to 
altered patterns of HMC-1 and HASM cell interactions.  The effects of IL-33 
on adhesion molecule expression of HMC-1 cells were also investigated, 
revealing some interesting results.   
  ICAM-1 expression on IL-33 treated HMC-1 cells revealed a clear pattern 
over the 48 hours of exposure.  The highest expression of ICAM-1 on the IL-33 
treated HMC-1 cells was at 20 hours, which was 95.32% compared to the 
ICAM-1 expression of TNF-α treated HMC-1 cells.  As a consequence of this 
result, it was repeated 7 times to ascertain whether this pattern was 
reproducible.  The mean value from the 7 results of ICAM-1 expression on  
IL-33 treated HMC-1 cells after 20 hours was 88.46%, compared to the  
ICAM-1 expression of TNF-α treated HMC-1 cells.  Using the students’ 
unpaired t-test to compare ICAM-1 expression of HMC-1 cells treated with  
IL-33 for 20 hours and TNF-α with the untreated group, revealed statistical 
significance in both cases (P<0.01).   
  IL-33 mRNA has been shown to be expressed on HASM cells, so theoretically 
these cells should be able to release IL-33 when stimulated (Schmitz et al., 
2005).  HMCs present in the early phase reactions of asthma could provide this 
stimulation.  Since the IL-33 receptor, ST2, is present on cultured bone 
marrow-derived
 immature mast cells, human peripheral and cord blood-derived 
CD34
+ progenitor mast cells and mature mouse mast cells (Mortiz et al., 1998, 
Ali et al., 2007, Allakhverdi et al., 2007), HMCs should also become 
  88stimulated by IL-33.  Stimulated HMCs would result in an increase in ICAM-1 
expression (as suggested in the present study), potentially leading to increased 
interactions between HASM cells and HMCs.   
  Events that follow the interactions mentioned above could be cyclic in nature.  
For example; HMCs present in early phase asthmatic reactions stimulate 
HASM cells.  They then release IL-33, which in turn increases ICAM-1 
expression on HMCs leading to increased HASM interactions/adhesion as well 
as potentially increasing HMC mediator release.  At first, HMC mediator 
release would involve low levels of TNF-α, heparin, histamine and PGE2.  
These mediators are thought to have a proliferative effect on HASM cells and 
could be linked to the several pathological features associated with asthma; 
airway remodelling for example (Amrani et al., 1996).  In particular, TNF-α is 
thought to induce HASM cell proliferation via the TNF-α p55 receptor (Amrani 
et al., 1996).  When IL-33 levels begin to rise, the mediators released from 
HMCs begin to increase as well, potentially having an anti-proliferative effect 
on HASM cells (Stewart et al., 1995).  The mediators released may dissipate in 
a transient fashion, leading to another round of HASM stimulation by activated 
HMCs during the early phase asthmatic reaction.         
  Previous studies implicated TNF-α as a positive inducer of ICAM-1 
expression on HMC-1 cells, supporting the use of TNF-α as a positive control 
in the present study (Tsang et al., 2005).  Several other studies have also 
identified the IL-33 receptor complex (ST2) present on a variety of mast cell 
sources, including; differentiated murine-derived mast cells, HUCBMCs and 
CD34
+ progenitor-derived mast cells  
  89(Ali et al., 2007, Allakhverdi et al., 2007, Iikura et al., 2007).  Since TNF-α is 
one of the primary mediators released from mast cells, its release could be 
partly due to IL-33 stimulation.  Once stimulated and subsequently activated,  
TNF-α release would have an autocrine effect on the activated mast cell 
resulting in an up-regulation of ICAM-1 expression.  This would consequently 
influence mast cell/HASM cell interactions/adhesion.    
  HMC-1 cells exposed to IL-33 for 20 hours were used for the remainder of the 
ICAM-1 experiments, since this time-frame resulted in optimal ICAM-1 
expression.  Using anti-TNF-α therapies also helped to test the above 
hypothesis.  ICAM-1 expression on HMC-1 cells exposed for 20 hours to 
Adalimumab (100ng/ml) with TNF-α, Etanercept (100ng/ml) with TNF-α and 
receiving no treatment compared to TNF-α treated HMC-1 cells were; 58.91%, 
62.62%, 53.82% and 100% respectively (Figure 9).  The concentration of  
anti-TNF-α therapies used (100ng/ml) resulted in adequate numbers of gated  
HMC-1 cells; therefore these concentrations were deemed unlikely to be toxic.  
ICAM-1 expression on the HMC-1 cells treated with TNF-α and Adalimumab 
resulted in a 42.09% decrease compared to the HMC-1 cells treated with only 
TNF-α.  For the HMC-1 cells treated with Etanercept and TNF-α, there was a 
38.38% decrease in ICAM-1 expression.  These results are relatively 
comparable with the untreated HMC-1 cells.  This evidence further supports 
previous studies (Tsang et al., 2005) that TNF-α is a potent inducer of  
ICAM- expression on HMC-1 cells, since the anti-TNF-α therapies lead to an 
average 40.24% decrease in ICAM-1 expression.   
  Using a one way ANOVA statistical test to compare ICAM-1 expression of 
HMC-1 cells treated with Adalimumab and Etanercept for 20 hours  
  90(with TNF-α) and the untreated group with HMC-1 cells treated with TNF-α, 
revealed statistical significance in all 3 cases (P<0.05) (Figure 9).  Post hoc 
analysis of the results (Tukey test with a Bonferroni adjustment) specifically 
identified the HMC-1 cells treated with Adalimumab and Etanercept for 20 
hours (with TNF-α) and the untreated group as being statistically different to 
the HMC-1 cells treated with TNF-α, at the 99% confidence level.  The 
statistical tests were based on 4 repeated experiments, revealing statistical 
significance at the 95% confidence level for the ANOVA test, and for the post 
hoc analysis, the confidence level increased to 99%.   
  ICAM-1 expression on HMC-1 cells exposed for 20 hours to Adalimumab 
(100ng/ml) with IL-33, Etanercept (100ng/ml) with IL-33 and receiving no 
treatment compared to IL-33 treated HMC-1 cells were; 57.47%, 60.76%, 
53.82% and 88.46% respectively (Figure 12).  The anti-TNF-α therapy results 
at the concentrations stated (HMC-1 cells treated for 20 hours) represent mean 
values taken from 4 repeated experiments.  ICAM-1 expression on the HMC-1 
cells treated with IL-33 for 20 hours and Adalimumab resulted in a 30.99% 
decrease compared to the HMC-1 cells treated with IL-33 for 20 hours alone.  
For the HMC-1 cells treated with Etanercept and IL-33 for 20 hours, there was 
a 27.70% decrease in ICAM-1 expression.  The ability of the anti-TNF-α 
therapies to down-regulate ICAM-1 expression on the HMC-1 cells was 
significantly high, using both TNF-α and IL-33 (20 hour exposure) treated 
HMC-1 cells.  The decrease in ICAM-1 expression using the anti-TNF-α 
therapies with TNF-α treated HMC-1 cells lead to a greater reduction compared 
to the IL-33 treated HMC-1 cells (20 hours exposure).  This could be because 
IL-33 stimulated HMC-1 cells produce less TNF-α compared to adding TNF-α 
  91to the HMC-1 cells.  This may also indicate that IL-33 could have other effects 
on the HMC-1 cells that lead to an up-regulation of ICAM-1 expression, 
independent of the autocrine effects of TNF-α.   
  Interestingly, the Adalimumab seemed to have a greater effect on HMC-1 cell 
reduction of ICAM-1 expression, treated with both IL-33 for 20 hours and 
TNF-α.  Adalimumab’s mode of action binds to the TNF-α, preventing it from 
binding to its cell surface receptor.  Adalimumab seemed to be more effective 
than Etanercept, since Adalimumab binds to the TNF-α receptor preventing 
TNF-α from binding to the HMC-1 cell.   
  Using a one way ANOVA statistical test to compare ICAM-1 expression of 
HMC-1 cells treated with Adalimumab and Etanercept for 20 hours (with IL-
33) and the untreated group with HMC-1 cells treated with IL-33, revealed 
statistical significance in all 3 cases (P<0.05) (Figure 12).  Post hoc analysis of 
the results (Tukey test with a Bonferroni adjustment) specifically identified the 
HMC-1 cells treated with Adalimumab and Etanercept for 20 hours (with IL-
33) and the untreated group as being statistically different to the HMC-1 cells 
treated with IL-33, at the 95% confidence level.  Statistical differences were 
obtained between all groups, using only 4 repeated experiments.   
  Several other adhesion molecules have also been implicated with the adhesion 
of HLMC to HASM cells, including integrins α4 and β1 (Yang et al., 2006).  
Since IL-33 revealed interesting results in relation to ICAM-1 expression on 
HMC-1 cells, its influence on the expression of other adhesion molecules 
present on HMC-1 and HASM cells were also investigated.    
  The MFI percentages of integrin-α4 expression compared to TNF-α over the 
time course; 0, 1, 18, 21, 24, and 48 hours exposure to IL-33 were; 28.57%, 
  9245.93%, 57.49%, 42.70%, 66.91% and 44.77% respectively (Figure 13).  The 
expression of integrin-α4 on HMC-1 cells revealed a somewhat erratic pattern, 
after exposure to IL-33 (100ng/ml) over the time periods studied.  However, 
HMC-1 cells exposed to IL-33 for 24 hours were shown to promote the greatest 
increase in up-regulating integrin-α4 expression over the time course carried 
out (Figure 13).  This up-regulation is represented graphically in the form of 
FACS plots, where a slight shift away from the isotype control is evident 
(Figure 14).  It is interesting to note that integrin-α4 expression on untreated 
HMC-1 cells reveals only a slight shift away from the isotype control, with 
TNF-α making somewhat of a modest shift away from the isotype control as 
well.  Taking these results together with the time-course results, IL-33 and 
TNF-α seemed to have little effect on integrin-α4 expression on HMC-1 cells.     
  Integrin-α4 expression on HMC-1 cells exposed to IL-33 (100ng/ml) for 24 
hours and receiving no treatment compared to TNF-α treated HMC-1 cells 
were; 66.91%, 44.77% and 100% respectively (Figure 15).   
  Using the students’ unpaired t-test to compare integrin-α4 expression of 
HMC-1 cells treated with IL-33 for 24 hours with the untreated group revealed 
no statistical difference (P>0.05).  Conversely, integrin-α4 expression of  
HMC-1 cells treated with TNF-α compared to the untreated group were 
statistically different at the 95% confidence level (Figure 15).  Again, these 
results further support the notion that HMC-1 cells treated with IL-33 had little 
effect on integrin-α4 expression.   
  The MFI percentages of integrin-β1 expression compared to TNF-α over the 
time course; 0, 1, 18, 21, 24, and 48 hours exposure to IL-33 were; 72.80%, 
103.63%, 110.79%, 116.55%, 98.17% and 114.62% respectively (Figure 16).  
  93The expression of integrin-β4 on HMC-1 cells exposed to IL-33 (100ng/ml) 
revealed little variation over the time frame studied.  However, HMC-1 cells 
exposed to IL-33 for 21 hours were shown to promote the greatest increase in 
up-regulating integrin-β1 expression over the time course carried out  
(Figure 16).  This up-regulation is represented graphically in the form of FACS 
plots, where a shift away from the isotype control is evident (Figure 17).  
Integrin-β1 expression on untreated and TNF-α treated HMC-1 cells also reveal 
a shift away from the isotype control.  It is interesting to note that HMC-1 cells 
treated with IL-33 for 21 hours produced a greater increase in the expression of 
integrin-β1 compared to TNF-α treated HMC-1 cells (Figure 17).  Taking these 
results together with the time-course results, IL-33 and TNF-α seemed to have 
little effect on integrin-β1 expression on HMC-1 cells. 
  Integrin-β1 expression on HMC-1 cells exposed to IL-33 (100ng/ml) for 21 
hours and receiving no treatment compared to TNF-α treated HMC-1 cells 
were; 116.55%, 72.80% and 100% respectively (Figure 18). 
  Using the students’ unpaired t-test to compare integrin-β1 expression of 
HMC-1 cells treated with IL-33 for 21 hours and TNF-α with the untreated 
group, revealed no statistical difference in both cases (P>0.05).  Again, these 
results further support the notion that HMC-1 cells treated with IL-33 had little 
effect on integrin-β1 expression.  
  Both IL-33 (100ng/ml) and TNF-α (20ng/ml) seemed to have little effect on 
integrin-α4 and integrin-β1 expression on HMC-1 cells.  Even exposure to the 
above cytokines over 48 hours seemed to have little effect on integrin-α4 and 
integrin-β1 on the HMC-1 cells.  Bone marrow cells induced to differentiate 
  94into
 mast cells via IL-3 express the murine integrin alpha 4 and beta 1 proteins.  
Surface staining analysis
 indicates that these cells also express an  
alpha 4-containing integrin complex
 throughout the differentiation process 
(Gurish et al., 1992).  Since the experiments conducted in this investigation 
involved analysing each integrin subunit individually, IL-33 and TNF-α might 
have an effect on the integrin complex α4β1, as apposed to having an effect on 
the individual subunits. 
  The current investigation has revealed several interesting results to add to the 
body of research aimed at elucidating the molecular as well as immunological 
mechanisms involved with asthma.  In particular, the role of IL-33 has been 
implicated in a variety of immunological pathways that contribute not only to 
the pathogenesis of asthma, but to other autoimmune diseases as well, atopic 
dermatitis for example (Allakhverdi et al., 2007).  A role for ST2/IL-33
 in 
human allergic diseases is supported by the recent finding
 that an SNP in the 
ST2 promoter results
 in enhanced ST2 expression and is associated with an 
increased
 risk of developing atopic dermatitis (Shimizu et al., 2005).   
  Recommendations for future work include; using human umbilical cord blood 
stem cells exposed to IL-3 and SCF to enable maturation of CD34
+ progenitor 
cells into HMCs.  This would represent an improvement on using HMC-1 cells, 
since induced HMCs from human umbilical cord blood stem cells represent a 
more realistic representation of the cells involved within a human asthmatic 
patient (Allakhverdi et al., 2007). Using human lung mast cells (HLMCs) from 
donor lung tissue would also represent an improvement to using HMC-1 cells, 
for the same reasons mentioned above (Yang et al., 2006).  Using alternative 
sources of HMCs would require additional applications to an ethics committee, 
  95as well as obtaining consent from the patients involved in any potential future 
studies.   
  In addition to using alternative mast cell sources, analysing other cell surface 
adhesion molecules present on HMC-1 cells would also help to further expand 
the current methodology developed.  TSLC-1 would be an interesting adhesion 
molecule to investigate, particularly since Yang et al., implicated TSLC-1 as 
being important in the recruitment and retention of HLMCs by HASM in 
asthma (Yang et al., 2006).   
  Research into positive inducers of adhesion molecules present on HMC-1 cells 
(mast cells in general) would also be useful, especially since the results for 
integrin α4 and integrin β1 subunits revealed little change in expression after 
exposure to IL-33 (100ng/ml) and TNF-α (20ng/ml).  Using a primary antibody 
that targets the whole integrin α4β1 subunit on the HMC-1 cells would also be 
beneficial.  Further analysis using Flow cytometry after exposure to IL-33 and 
TNF-α etc could then be performed.   
  Additional in vitro work to further elucidate IL-33s role in the interaction of 
mast cells and HASM cells could involve setting up a time course using IL-33 
on HMC-1 cells, investigating ICAM-1 expression again but also checking the 
tissue culture supernatant for TNF-α production to see if there is a correlation 
e.g. is IL-33 stimulating the mast cells to produce TNF-α production, having an 
autocrine effect resulting in an up-regulation of ICAM-1 expression.  Setting up 
an adhesion assay would also help to investigate the chemotactic role of HASM 
cells on mast cells, and whether IL-33 has any influence on the resultant 
adhesion involved in the retention of mast cells.  The CXC10/CXCR3 axis has 
been shown to mediate HLMC migration towards HASM cells from asthmatic 
  96patients (Brightling et al., 2005), so this area of research might reveal some 
interesting results.  For example; mast cells and HASM cells could be 
fluorescently labelled, counted and left in culture medium, exposed to IL-33 
and TNF-α over a time-course, and then analysed using FACS to see if the 
numbers of mast cells present remain the same after the non-adherent mast cells 
are washed off.     
  The next logical step from in vitro experiments would be looking at in vivo 
models.  In particular, asthma induced mice could be exposed to IL-33 at 
different concentrations and then processed to confirm if asthma has been 
induced.  For example, assessment of the BAL fluid for various immune 
molecules, analysis of the blood and tissue sections taken for histological 
analysis.  In particular, localisation of the murine mast cells would be 
interesting to investigate with the asthma phenotype.   
  It is hoped that the work presented here will provide the basis for future 
investigations into a highly interesting area of immunological research.  
Improved understanding of the molecular and immunological mechanisms that 
contribute to the aetiology and pathogenesis of the asthma phenotype will 
hopefully one day lead to improvements in the diagnosis and treatment of the 
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intensity ( all curves 
are roughly 
gaussian)                
ICAM-1 
expression      
                             
   IL-33 48 hours  26 24 20 18  1 no IL-33 
TNF 
alpha    isotype
A  3713.62     3151.32    2997.52  2216.06    4778.82 38.88
   2844.03     4366.66    3387.5        5884.97   
                        3904.093   
                             
mean  3278.825     3758.99    3192.51  2216.06    4855.961 38.88
% of TNF  67.52165019     77.40980622    65.74414  45.63587    100 0.800665
                             
                             
B     288.53 379.03 433.98       254.24 429.35 6.9
      322.65 273.27 384.57               
                             
mean     305.59 326.15 409.275       254.24 429.35 6.9
% of TNF     71.17503203 75.96366601 95.3243275       59.21509 100 1.60708
                             
   48  26 24 20 18  1         
mean of % 
TNF    67.52165019  71.17503203 76.68673611 95.3243275 65.74414 45.63587 59.21509 100 1.752711
 
  117   
Mean immunofluorescence intensity 
(all curves are roughly gaussian)                
                    
   Ent IL-33  ENT TNF  ENT 
ADA  
IL-33    ADA  TNF  ADA
                    
290708 100.86 117.62 79.59 96.49 111.24 113.54
100ug/ml 114.93 123.77 76.58 74.17 110.28 82.1
                    
 107.895 120.695 78.085 85.33 110.76 97.82
mean % of TNF  58.33108072 65.2511218 42.21495378 46.13181 59.87998 52.88425
                    
030708 146.65 223.28 120.38 198.31 211.47 112.67
100ng/ml 283.46 164.67 172.9 176.58 172.59 130.24
100ug/ml                   
                    
 215.055 193.975 146.64 187.445 192.03 121.455
mean % of TNF  63.19570967 57.00117543 43.09138995 55.08228 56.42962 35.69057
                    
                    
                    
                    
070808 93.98 115.17 52.5 101.83 112.39 89.7
100ng/ml 93.4 104.13 65.45 90.5 84.86 71.76
                    
 93.69 109.65 58.975 96.165 98.625 80.73
mean % of TNF  58.30843913 68.24122479 36.70338561 59.84877 61.37976 50.24272
  118      
IL-33 all 
20 hours    
ICAM-1 
expression                   




IgG1    
IL-33 
IgG1     no IL-33  IL-33 20   TNF  isotype 
         50ng/ml  100ng/ml  50ng/ml  100ng/ml             
   290708 56.28              94.82  82.5 184.97 2.01
ENT/ADA  100ug/ml  61.77              76.35  108.46      
     59.025              85.585  95.48 184.97 2.01
  
mean % 
of TNF  31.91058              46.26967  51.61918 100 1.086663
                                
   030708 118.37              229.51  270.3 340.3 3.65
ENT/ADA  100ng/ml  101.85                         
IgG1  100ug/ml                            
     110.11              229.51  270.3 340.3 3.65
  
mean % 
of TNF  32.35674              67.44343  79.42991 100 1.072583
                                
        
IL-33 
IgG1                      
      100ng/ml  50ng/ml  100ng/ml                   
ENT/ADA  070808 54.28  60.94 57.9       81.26  122.72 160.68 4.58
   100ng/ml  113.71  93.57 65.63          88.64      
                                
     83.995  77.255 61.765       81.26  105.68 160.68 4.58
  
mean % 
of TNF  52.27471  48.08003 38.43976       50.57257  65.77048 100 2.850386
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Mean immunofluorescence 
intensity (all curves are 
roughly gaussian)                   
                       
   alpha 4                   
   IL-33 48  24 21 18 1 no IL-33  TNF 
                       
110708 3.45  10.89 3.86 4.83 4.07 2.56 9.18
   5.9  5.83 4.75 9.73 5.52      
                       
 4.675  8.36 4.305 7.28 4.795 2.56 9.18
mean % 
of TNF  50.92592593  91.06754 46.89542 79.30283 52.23312 27.88671 100
                       
10808 6.17  7.66 5.93 6.47 5.53 4.3 23.76
   5.18  4.91 5.39 4.02 6.12    5.64
                       
 5.675  6.285 5.66 5.245 5.825 4.3 14.7
mean % 
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Integrin alpha 4 
beta 1 
expression                      
                          
    beta 1                      
   IL-33 48  24 21 18 1 no IL-33  TNF  isotype 
                          
110708 29.25 23.95 46.36 43.76 37.97 12.32 17.04 13.81
   35.15  27.17 22.46 18.86            
                          
mean 32.2  25.56 34.41 31.31 37.97 12.32 17.04 13.81
% of TNF  188.9671  150 201.9366 183.7441 222.8286 72.30047 100 81.0446
                          
10808 61.01 58.13 58.54 53.81 55.41 48.6 47.99 12.28
   48.55  57.21 56.53 56.15 6         
                          
mean 54.78  57.67 57.535 54.98 30.705 48.6 47.99 12.28
% of TNF  114.1488  120.1709 119.8896 114.5655 63.98208 101.2711 100 25.58866
                         
          090808  40.92 15.27 26.4 35.22 22.35 32.22 71.86 3.37
  17.62  19.73 13.59 13.75 12.27         
                         
29.27 17.5 19.995 24.485 17.31 32.22 71.86 3.37
mean % of 








ICAM-1(%)                         
                             
  
IL-33 48 
hours        26 24 20 18 1  no IL-33 
TNF 
alpha isotype
                             
A                            
gated from isotype = 
2.2%  91.21     93.73    95.01 97.46     84.21 2.2
   96.5     90.13    92.31       67.73   
                        87.93   
B                            
gated from isotype = 
1.91%     99.54 99.95 99.65       99.45 99.77 1.91
      100 99.74 99.62               
                             
            97.38       97.24 94.92 2
            93.46       96.16      
            97.86       86 89.64 2.29
            90.29               
            83.4       99.16 98.92 2.48
                             
                             
            92.478       98.345 84.91 2.036667
            99.635       93.77333 94.49333 2.385
 




ICAM-1          
IL-33 all 
20 hours    
                       
      Ent IL-33  ENT TNF  ENT  ADA IL-33 ADA TNF  ADA 
                       
   290708 95.49 94.15 94.56 95.21 94.5 97.01
   100ug/ml  96.6 97.04 94.67 96.07 93.89 95.24
   gated from isotype = 2%                   
                       
   030708 96.67 97.96 98.51 97.5 99.37 96.59
ENT/ADA    100ng/ml 97.5 97.83 99.07 99.43 99.26 99.82
IgG1  100ug/ml                   
   gated from isotype = 1.83%                   
                       
                       
                       
                       
   070808 92.3 87.29 81.96 92.49 89.05 78.67
ENT/ADA    100ng/ml 91.3 85.51 84.21 91.4 82.51 87.67






  123    ICAM-1 expression                       
                          
   TNF IgG1  IL-33 IgG1        no IL-33  IL-33 20   TNF  isotype 
                          
   92.17  94.92       97.24 97.38 94.92 2
   85.83  95.27       96.16 93.46      
                          
                          
 ENT/ADA  98.93  98.79       99.16 97.86 98.92 2.48
IgG1  99.04  98.72                  
                         
                          
                          
                          
   TNF IgG1     IL-33 IgG1               
   50ng/ml  100ng/ml  50ng/ml  100ng/ml             
 ENT/ADA  84.34  64.85 78.32 83.47 86 90.29 89.64 2.29
  80.62  84.44 89.32 77.17    83.4      








  124  
  
Proportion of cells 
expressing Integrin 
alpha 4                   
                       
   alpha 4                   
   IL-33 48  24 21 18  1 no IL-33  TNF 
                       
110708 11.54 15.7 10.38 17.65  12.14 3.61 47.67
gated from isotype = 2.21%  40.85 22.94 27.37 21.92  8.12      
                       
                       
                       
                       
10808 20.03 32.54 11.87 23.47  7.06 11.67 41.91
gated from isotype = 2.32%  10.44 8.41 11.75 8.89      26.94 14.56
                       
                       
                       
                       
                      





  125  
     
 Proportion of 
cells 
expressing 
Integrin beta 1                   
                          
    beta 1                      
   IL-33 48  24 21 18 1 no IL-33  TNF  isotype 
                          
110708 96.48 97.61 99.74 99.04 97.11 69.9 31.09 2.21
gated from 
isotype = 2.21%  91.22  91.91 92.31 94.4            
                          
                          
                          
                          
10808 99.37 99.53 99.43 99.47 99.62 98.84 27 2.32
gated from 
isotype = 2.32%  99.32  99.57 99.47 99.58 22.68    99.03   
                          
                          
                          
                          
090808 93.03 44.42 77.65 92.13 66.11 89.16 98.1 2.12
gated from 
isotype = 2.12%  55.46  56.9 39.65 34.21 28.04         
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